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ABSTRACT 
 
 
Current chemotherapeutic treatments for cancer utilize systemic administration of 
cytotoxic drugs and produce many side effects in healthy tissues, making optimal treatment of 
cancer hard to achieve. Tumor targeted chemotherapy treatment enables these drugs to 
selectively treat cancer cells with minimal effect on healthy tissues. By using targeting agents 
that specifically recognize receptors present only on cancer cells and neovasculature, tumor-
specific chemotherapy can be achieved. These targeting agents can be used to direct nanoparticle 
drug delivery carriers in order to deliver greater drug doses to tumor tissue, enhance 
bioavailability, pharmacokinetics and pharmacodynamics of many chemotherapy drugs, as well 
as reduce toxicity and undesirable side effects in vivo.  
The development, optimization and evaluation of tumor-specific drug delivery systems 
composed of second generation ‘nanosponges’ has been investigated as a potential therapeutic 
for the treatment of lung cancer. This drug delivery system is hypothesized to optimize 
bioavailability and therapeutic efficacy of chemotherapy drugs in tumors, reduce side effects in 
normal tissues, and result in improved cancer treatment. These nanosponges have been 
developed from optimized linear polyester copolymers using tin (II) triflate catalyzed ring-
opening polymerization methods. They contain functional groups for modification with targeting 
and imaging agents in order to both target malignant tumor cells as well as visualize them in 
vitro and in vivo. Tumor targeting peptides such as cyclo-RGD that target the αvβ3 integrin 
receptor, and the HVGGSSV peptide that target radiation-inducible tax-interacting protein 1 
receptor allow for tumor-specific targeting of nanosponges. These nanosponges enable 
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controlled linear drug release of small molecule chemotherapeutics that can optimize 
combination chemotherapy strategies for the treatment of lung cancer.  
Due to their biodegradability, high encapsulation efficiency, and sustained linear drug 
release profiles, these optimized nanosponges are ideal for the encapsulation and controlled 
release of chemotherapy drugs. The applicability of a HVGGSSV peptide targeted nanosponge 
drug delivery system for sequential administration of a microtubule inhibitor (paclitaxel) and 
topoisomerase I inhibitor (camptothecin) was investigated in a lung cancer mouse model. 
Combination therapy with these two drugs will allow for multiple mechanisms of action for 
inhibiting cancer growth, resulting in enhanced cytotoxicity when delivered in varying 
sequences.  
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CHAPTER 1 
 
INTRODUCTION 
 
Cancer chemotherapy 
The majority of cancers diagnosed are solid tumors that can be surgically resected, 
however, remaining malignant cells are difficult to detect and remove and can potentially spread 
after surgical treatment.1-4 Chemotherapy and radiotherapy are commonly used as second line 
treatments to eradicate remaining cancer cells after surgery, and in cases where surgery is not 
possible as first line treatments.1 Achieving complete eradication of cancer cells has proven to be 
a challenge due not only to metastatic cells, but also to poor bioavailability of commonly used 
chemotherapy drugs, limited dosing due to toxicity, damage to normal tissues as a result of 
systemic administration of cytotoxic drugs, multidrug resistance (MDR), and low solubility of 
hydrophobic drugs under physiologic conditions.1-8 Current chemotherapy regimens require 
systemic administration of cytotoxic drugs intravenously, with multiple rounds of treatment 
usually needed. Achievement of a high enough dose to kill the cancer while maintaining 
tolerability to the patient remains a challenge.1-8 Additionally, many cancer patients are 
immunocompromised and the elevated toxicity resulting from certain treatment regimens is not 
well tolerated, possibly even contributing to patient mortality.1-8 Typical cancer drugs are also 
highly hydrophobic and suffer from poor water solubility, requiring them to be administered 
along with a pharmaceutical grade solvent (such as castor oil, ethanol, and surfactants).2-8 These 
solubility enhancing solvents cause severe allergic reactions and other undesirable side effects in 
patients, making them difficult to tolerate for immunocompromised cancer patients.2-8 As a 
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result, systemic chemotherapy continues to have major drawbacks that impact treatment 
outcomes, patient survival and quality of life. Alternative formulations and drug delivery systems 
have been actively investigated to circumvent these problems. Nanoparticle drug delivery 
provides advantages over systemic ‘free’ drug treatment by allowing for more effective 
therapeutic doses to be administered while mitigating many of the side effects. 
 
Nanotechnology for targeting, imaging and therapy  
Development of nanoscale carriers for treatment of cancer has been of particular interest 
since the use of nanoparticles for delivery of chemotherapeutics to malignant tumors offers 
solutions to the problems associated with chemotherapy administration, dosing and formulation 
issues.2-8 Nano-sized carriers are ideal for delivering drugs and imaging agents because they can 
control the release of drug locally, target surface receptors on cancer cells and neovasculature, 
and allow imaging of biodistribution in vivo.2-8 These multifunctional ‘nanotheranostics’ can 
simultaneously deliver and release therapeutic agents, and be used as contrast agents for 
molecular imaging, making them ideal for both therapy and diagnosis (Figure 1.1).5,6 This 
versatile nanoparticle is particularly suited to applications where treatment must be adapted to 
the continuously changing needs of the patient throughout the course of treatment. Additionally, 
it allows for greater convenience for patients with a single treatment serving multiple functions. 
The ability to monitor the effectiveness of treatment using imaging technology is also of huge 
benefit to physicians as it allows for optimized treatment protocols, and greater flexibility for 
switching from ineffective drugs to more effective ones in a timely manner.  
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Nanocarrier 
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Targeting 
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Nanotheranostics 
 
Figure 1.1.  Nanotheranostics combine nanotechnology with therapy and diagnosis. 
 
Nanoparticle materials 
Nanoparticles have been made from many different materials including synthetic and 
natural polymers, lipids, metals and other inorganic materials. Examples of nanoparticles formed 
from polymers include polymer-drug conjugates, micelles, dendrimers, and nanogels.2-8 
Depending on the application and physiological environment, materials can be rationally 
designed to enhance biocompatibility as well as optimize physicochemical properties.  
Biodegradable polymers have been frequently used for the design of nanoparticles for 
drug delivery applications since they can degrade under physiological conditions, gradually 
release drug in a time-dependent manner, and are physiologically compatible.11,14,16,57 In order 
for a polymer to be considered ‘biodegradable’, it must be capable of undergoing either 
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hydrolytic, enzymatic or oxidative degradation processes.11,4,16 Hydrolytic and enzymatic 
degradation typically occur under physiological conditions given the abundance of water 
molecules and enzymes (such as hydrolases and esterases) available in blood and tissues, and are 
frequent degradation pathways for polymers used in the pharmaceutical industry.11,14,16 
Biocompatibility of these polymers is also important for polymers that remain in vivo for 
extended periods of time, thus the polymer itself and its degradation products must not be toxic 
or generate an immune response. Consequently, biodegradable polymers are highly suitable for 
delivering drugs due to greater biocompatibility and decreased immunogenicity, as well as 
controlled release of drugs via degradation.11,14,16 In addition, functional groups can be built into 
these polymers to allow addition of targeting units such as peptides and antibodies, as well as 
imaging probes for visualization.11-19 Depending on the polymer type, solubility and crystallinity 
can also be tuned to deliver unique polymers customized for specific applications.11-19, 68-70  
A variety of biodegradable polymers have been previously studied including polyesters, 
polyanhydrides, polyurethanes, and polyacrylates.11,14,16 These polymers can range from 
hydrophobic to hydrophilic, with varying degrees of hydrophobicity and hydrophilicity produced 
with copolymer composition. Of these, biodegradable polymers such as poly(lactide)-co-
(glycolide) (PLGA) have been widely used for nanoparticle drug delivery systems due to 
controlled degradation and drug release properties and favorable biocompatibility 
profiles.10,20,67,82-85 However, production of a sustained, linear drug release profile has been 
difficult to achieve in the past due to greater amounts of drug released initially (known as the 
‘burst effect’).12-19  Greater drug encapsulation efficiency, as determined by the amount of drug 
actually loaded into a nanoparticle compared to amount of drug attempted, has also made 
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biodegradable polymer-based nanoparticle preferable over other types of nanoparticles  for drug 
delivery applications.10-20  
The main advantage of using synthetic polymers for nanoparticles lies in their ability to 
be designed to accommodate particular applications. This “tunability” exploits the different 
properties of polymers and copolymer combinations to produce nanoparticles with desirable 
properties. Examples of properties that can be “tuned” include particle size, surface properties 
(charge, hydrophobicity, morphology, and functionalities) and payload density.2-8 In addition, 
several of these factors such as size, surface modification and functionalization with targeting 
ligands can affect clearance and biodistribution of nanoparticles in vivo.2-8 Nanoparticle size has 
been known to affect in vivo clearance, with a range of 10-120 nm considered an optimal range.2-
8 Nanoparticles smaller than 10 nm are rapidly cleared by the kidneys, while those in the upper 
size range can potentially get trapped within tumors via enhanced permeability and retention 
(EPR) effect.2-8  Surface charge can also affect nanoparticle internalization within tumor tissue 
and cells, with a slight negative surface charge (-2 to -5 mV) allowing the nanoparticles to better 
penetrate into tumor cells.2-8 Minimization of size and charge reduces scavenging by 
macrophages and the reticuloendothelial system (liver, spleen, lymph and bone marrow cells). 
Use of a neutral polymer such as polyethylene glycol (PEG) can also reduce surface charge, 
reduce aggregation caused by interactions between nanoparticles, and allow nanoparticles to 
evade the reticuloendothelial system and reduce immunogenicity (interaction with immune cells 
and provocation of an immune response).2-8 In addition, surface modification with PEG increases 
circulation time. Hydrophobicity can be tuned in polymeric nanoparticles by altering the 
monomer type, polymer chain length and molecular weight, and addition of other modifiers such 
as PEG to enhance hydrophilicity.2-8,44-46 Nanoparticle morphology can be affected by changes in 
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molecular arrangement, with variation in percent amorphous and crystalline regions producing 
changes in overall packing structure. Surface functionalities can be tuned with covalent 
attachment of peptides, antibodies, aptamers and other small molecule targeting ligands.2-8 
Surface density of these targeting ligands can be increased or decreased according to presence of 
functional groups available for bonding. Nanoparticles also enable multivalency, with multiple 
ligands on nanoparticle surfaces increasing likelihood of interaction with cell surface receptors.2-
8,35-40 Small molecules such as chemotherapy drugs, proteins and siRNA can be loaded within 
nanoparticles in varying degrees depending on nanoparticle size, porosity and hydrophobicity.  
 
Nanoparticle cancer therapeutics 
Nanoparticles are particularly useful for delivering small molecule drugs that are highly 
toxic, hydrophobic, and rapidly cleared in vivo. Use of nanoparticle carriers can safely solubilize 
these types of drugs, increase plasma half-life, deliver and release them within tumor tissues, 
vasculature and cells.  One of the major benefits of using nanoparticles in drug delivery 
applications is not only increased deposition of drugs within tumors, but also reduced systemic 
exposure.2-8,35-48 Toxic drugs have exposure limits that can prohibit treatment with optimal 
dosages needed for destruction of tumors. In order to avoid exceeding upper exposure limits and 
lethal toxicity levels, physicians are often forced to administer lower doses that may not be 
optimally effective. However, with nanoparticle drug delivery systems greater dosages can be 
achieved with lower side effects, allowing more optimal dosages to be administered with 
improved tolerability.2-8,35-48  Nanoparticle drug delivery can also be used for neoadjuvant 
chemotherapy, reducing the size of a tumor before more radical treatments are performed.2-8 This 
is important in cases where tumors in their original state are non-resectable due to close 
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proximity to major blood vessels, vital organs or extent of malignant tissue. Nanoparticle 
chemotherapy can allow more aggressive neoadjuvant treatments than systemic chemotherapy, 
potentially improving success of more radical treatments afterwards.2-8  
Depending on the particular drug, dosage, and treatment schedule, nanoparticle materials 
can be modified to provide the desired characteristics. These might include encapsulation of 
hydrophobic drugs, various administration methods, biodegradeability, controlled release, 
sustained release, and localized delivery of drug to maximize the therapeutic index and minimize 
systemic toxicity.2-8 Problems that have been encountered with some polymeric nanoparticles 
include potential chemical instability, limited bioavailability, and lack of site specificity.10-16 
These problems are often addressed by modifying the polymer composition and incorporation of 
tumor-specific targeting ligands.13,35,54 The design of the nanoparticles as well as their surface 
chemistry can be used to engineer nanoparticle carriers with properties that can enhance cancer 
treatment while minimizing side effects.  
A variety of chemotherapy drugs have been encapsulated including paclitaxel, 
dexamethasone, 5-fluorouracil, and etoposide.2-20 Applications for these types of drug delivery 
systems have increased over the last decade as more drugs have been encapsulated with greater 
efficiency.  Highly hydrophobic drugs in particular have benefited from the development of 
biodegradable nanoparticles because they are difficult to solubilize for intravenous injection, and 
require use of a pharmaceutical grade solvent or surfactant. In this work, a nanoparticle drug 
delivery system comprised of biodegradable copolymers has been used to deliver the 
chemotherapeutic drugs paclitaxel and camptothecin due to their hydrophobicity and poor water 
solubility (Figure 1.2). In addition, a less hydophobic drug, seliciclib, was also used for in vitro 
drug combination studies. 
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Paclitaxel Camptothecin Seliciclib
Structure
Formula C47H51NO14 C20H16N2O4 C19H26N6O
MW 853.9 348.4 354.5
Source Pacific Yew tree          
(Taxus brevifolia) 
Chinese happy tree 
(Camptotheca acuminata)
synthetic small molecule
Mechanism 
of Action mitotic inhibitor topoisomerase I inhibitor CDK (2,7,9) inhibitor
Indication breast, lung, ovarian,    
head and neck cancer
ovarian, lung, colon cancer lung cancer, leukemia,    
HIV, inflammation
MW: molecular weight; CDK: cyclin-dependant kinase
 
Figure 1.2.  Structures of chemotherapy drugs used in nanosponge drug delivery systems. 
 
In clinical applications, paclitaxel has been administered using Cremophor® EL, a 
pharmaceutical grade solvent, in order to enhance water solubility.2-20 However, low stability in 
circulation as well as significant side effects (neurotoxicity, hypersensitivity and allergic 
reactions) have made using these solvents undesirable and other formulations have been 
investigated. As a result, alternative nanoparticle formulations for taxanes have been developed 
and studied clinically including Abraxane®.2-20 Abraxane® is an albumin-based nanoparticle used 
to deliver paclitaxel, initially approved by the FDA for use in the treatment of breast cancer in 
2005, and also non-small cell lung cancer and pancreatic cancer in 2013 (Figure 1.3). 
Nanoparticle formulations of camptothecin have not been available on the market, but attempts 
have been made to modify the structure of camptothecin to enhance its water solubility, resulting 
in the analogues irinotecan and topotecan. Figure 1.3 shows other nanoparticle drug delivery 
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systems also approved by the United States FDA including several liposomal formulations for 
the anthracyline analogues doxorubicin (Doxil®) and daunorubicin (DaunoXome®), as well as 
vincristine (Marquibo®) and cytaribine (DepoCyt®).2-20 PEGylated drug compounds have also 
been approved for L-asparaginase (Oncaspar®) and pegfilgrastim (Neulasta®) for blood cancers 
and disorders relating to chemotherapy.2-20 
 
!!
FDA  Approved Nanoparticle Therapeutics for Cancer Treatment 
!!
Drug Delivery 
System 
Therapeutic 
Drug 
Commercial 
Name Indications 
FDA 
Approval 
!!
Albumin-bound 
paclitaxel (nab) Paclitaxel Abraxane
® breast, non-small cell lung cancer, pancreatic cancer 
2005, 2013 
2013 
!!Liposomes Vincristine Marqibo® Ph-  acute lymphoblastic leukemia 2012 
!!   Cytaribine DepoCyt® lymphomatous meningitis 2007 
!!   Doxorubicin Doxil® Kaposi's sarcoma, ovarian cancer 1995, 1999 
!!   Daunorubicin DaunoXome® Kaposi's sarcoma 1996 
!!PEGylated drug L-asparaginase Oncaspar® acute lymphoblastic leukemia 2006 
!!   Pegfilgrastim Neulasta® neutropenia 2002 
!! FDA: food and drug administration; nab: nanoparticle albumin bound; Ph- : Philadelphia chromosome negative;              
PEG: polyethylene glycol; PLA: polylactic acid !!  
Figure 1.3.  Nanoparticle drug delivery systems approved by the United States Food and Drug 
Administration for treatment of cancer.2-20 
 
In this study, biodegradable nanosponges were used as nanocarriers to deliver 
chemotherapy drugs to tumors. Due to a cross-linked polymeric architecture, controlled low dose 
drug release profiles were produced that were highly suitable for this application.86-88 
Furthermore, development of a tumor-specific drug delivery system that enhanced drug 
solubility, provided sustained low dose drug release, and could be used with different drug 
combinations provided a unique opportunity for maximizing the potential of chemotherapy while 
reducing the limiting toxicities that lower treatment efficacy. Therefore, biodegradable 
nanosponges were optimized to target and treat tumors. Due to their biodegradable nano-network 
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(a cross-linked 3-dimensional scaffold), drug can be loaded into nanosponges and released in a 
controlled fashion upon degradation in physiological conditions. These nanoparticles can be 
synthesized in different sizes and network densities, and can be functionalized with tumor 
targeting ligands and imaging agents to enable visualization in vivo.86-88 Moreover, hydrophobic 
drugs can be loaded into these nanosponges, enhancing solubility and producing formulations for 
parenteral administration. 
 
Tumor targeting  
In order to direct these nanoparticle carriers to specific sites, such as malignant tumors, 
targeting has played an increasingly important role in drug delivery systems. Both passive and 
active targeting strategies have been explored as ways to efficiently deliver drugs to tumors and 
enhance specificity.38-48  
Passive targeting of drug delivery systems utilizes the enhanced permeability and 
retention (EPR) effect to selectively accumulate in tumors instead of other tissues.38-48 By 
exploiting the greater permeability of tumor microvasculature and poor lymphatic drainage, 
nanoparticles greater than 50 kDa can be retained within tumor tissues.38-48 Since this method of 
targeting does not require the use of targeting units but relies more on nanoparticle size and 
molecular weight, it is known as a passive targeting strategy. While this method is useful for 
delivering and trapping high molecular weight drugs within tumor tissues, it is not as effective 
for low molecular weight drugs due to rapid washout by tumor vascular blood flow.38-48  In 
addition, variation between tumor types (and also within each individual tumor), size and 
location produces differences in blood vessel structure, and can impact treatment effectiveness.  
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Active targeting strategies require the use of receptor-ligand binding and are more 
specific in interaction and binding to tissue types and biomarkers for disease. Receptors present 
on the surface of cancer cells and their microvasculature can be targeted using peptides or 
antibodies that have high affinity and specificity for these receptors.38-48,63,64 There are a variety 
of commonly used targets including the αvβ3 integrin, tax-interacting protein 1 (TIP-1), 
epidermal growth factor receptor (EGFR), and vascular endothelial cell growth factor receptor 
(VEGF), among others.38-50,89-93 Conjugation of peptides or antibodies that target these receptors 
can enable a nanoparticle to home specifically to tissues that express these receptors. Use of 
active over passive targeting strategies presents advantages including receptor specific binding, 
delivery of small molecule drugs independent of size, and greater concentration of drug within 
the tumor compared to normal organs.   
 Tumor-specific targeting using radiation-inducible receptors has been demonstrated in 
various tumor models.89-93 Briefly, exposure of a solid tumor to sub-therapeutic levels of ionizing 
radiation is used to induce expression of receptors on tumor cells and neovasculature. Peptides 
developed using phage display technology can be targeted to these radiation-inducible receptors 
to enable tumor-specific binding.89-93,58-62 Use of these peptides in conjunction with 
nanoparticles, small molecule therapeutics and contrast agents can produce radiation-targeted 
drug delivery and imaging systems for cancer treatment. In this work, the tax-interacting protein-
1 (TIP-1) binding peptide (HVGGSSV) was used as a targeting ligand for tumor-specific 
delivery of chemotherapeutic drugs and imaging agents.90-93 This peptide was shown to bind to 
tumor cells exposed to a sub-therapeutic dose of 3 Gy ionizing radiation in lung, brain, breast, 
colon and prostate cancer models.90-93 By targeting chemotherapy drugs specifically to tumor 
tissue, greater concentrations of drug can be delivered to tumors without exposing healthy tissues 
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to cytotoxic drugs. Toxic side effects produced from non-specific delivery often compromise 
cancer treatment because of damage to healthy tissues and decreased tolerance in patients, 
causing suboptimal dosages and treatment protocols. Furthermore, radiation is widely used in the 
majority of cancer treatments along with chemotherapy and surgery.1-8 Technological and 
scientific advances have ensured accurate and efficient delivery of radiation dosages to tumor 
sites. Low dose radiation has also been reported to enhance drug delivery by inducing higher 
drug diffusion in solid tumors.1-8,90-93 Since radiation can be used in combination with 
chemotherapy drugs to enhance biological efficacy, it can also be used in conjunction with 
radiation-targeted drug delivery systems to optimize therapeutic efficacy.  
 Another target for tumors is the αvβ3 integrin adhesion receptor, a marker for 
angiogenesis. This integrin receptor has been widely used for both imaging and tumor targeted 
drug delivery, and it binds to a variety of peptides and proteins that contain the arginine-glycine-
aspartic acid (RGD) recognition motif.48-50 In particular, radiolabeled αvβ3 integrin antagonists 
(such as Cilengitide) have been used to monitor and treat cancers successfully in clinical trials.48-
50  
Molecular imaging  
Nanoparticles can be modified with imaging probes for a variety of molecular imaging 
applications, such as optical imaging and positron emission tomography (PET). Optical imaging 
modalities have the advantage of higher temporal resolution and safer use (since they do not use 
ionizing radiation or radioactive materials), but they provide lower spatial resolution and 
sensitivity in deep tissues.49,56,71-79 Some of the major limitations of optical imaging are related to 
the optical properties of tissues. A major limitation of optical imaging is the high scattering and 
absorption that occurs in biological tissues and the limited penetration of light in vivo.49,56,71-79 
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Since tissues and cells have numerous structures, boundaries and differences between each other, 
there are many different diffracting interfaces present. As a result, photons in the shorter 
wavelength visible range tend to be highly scattered, making it difficult to obtain depth resolved 
information from in vivo samples. 49,56,71-79 Some of these photons in the visible range (350–650 
nm) are also absorbed, due to the presence of cytochromes and hemoglobin within cells and 
tissues (see Figure 1.4).  Longer wavelength near infrared light (650-900 nm) tends to be 
absorbed and scattered less by tissues and cells, allowing light to penetrate deeper into tissue. 
49,56,71-79  As a result, many fluorescent probes have been developed for use in near-infrared 
imaging. Despite this, probes in the higher range (closer to 900 nm) tend to have lower signal 
intensity and are less bright compared to ones on the lower end (closer to 650 nm), so probe 
wavelength has to be chosen carefully in order to provide optimal imaging. In addition, 
photostability of fluorophores is important for optimum image quality and consistency, and must 
be taken into account when choosing a fluorophore.  
Near-infrared fluorescence (NIR) imaging is a particular kind of optical imaging that 
exploits the near-infrared range in the spectra to bypass the typical absorption and 
autofluorescence problems seen in optical imaging of biological tissues. 49,56,71-79 Lower 
autofluorescence allows for greater signal-to-background ratio. Typically, tissues exhibit a high 
photon absorbance in both the visible wavelength range (350–650 nm) and the infrared range 
(above 900 nm). 49,56,71-79 However, in the NIR range of 650–900 nm, the absorbance of water 
and tissues in the body is at a minimum and thus allows photons to penetrate tissue more 
efficiently and minimizes scattering. 49,56,71-79 Therefore, functional imaging of molecularly based 
events such as tumor-specific binding can be performed using optical imaging modalities in 
order to provide real time monitoring of biodistribution in vivo. 49,56,71-79  NIR imaging utilizes a 
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laser or bulb to excite a fluorophore at a specific wavelength, and the fluorophore then emits 
light at a different wavelength which then passes through a set of filters and is captured by a 
charge-coupled device (CCD) camera producing an image.49,56,71-79 Although more recent 
advances have led to the development of tomographic (3D) optical imaging methods, planar (2D) 
optical imaging is more common. 
 
 
Figure 1.4.  Absorption at near-infrared wavelengths by common biological molecules.74  
 
While optical imaging is commonly used in small animals, applications in humans and 
larger subjects have been severely limited due to problems with light attenuation. Nuclear 
imaging techniques, like positron emission tomography (PET), offer a major advantage over 
optical techniques due to greater penetration of tissues with radioactive tracers compared to 
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optical tracers.94-97 PET imaging provides superior sensitivity for imaging deeper tissues, but also 
presents challenges unique to radioactive tracers including development, half-life, and safety 
issues.94-97 One of the main considerations with PET imaging would include selection of a 
radiotracer whose half-life is compatible with the kinetics of the nanoparticle drug delivery 
system in vivo. Radiotracers with shorter plasma half-lives than the nanoparticle drug delivery 
systems they are being used to image would present problems with image quality and 
consistency, as the radiotracer would undergo radioactive decay at a faster rate that the 
nanoparticles are cleared, producing lower signal intensity due to radioactive decay rather than 
nanoparticle clearance.  
 
Drug quantification 
Both NIR and PET imaging are non-invasive tools for visualizing tumor targeting in vivo, 
and a complement to more direct chemical quantification such as mass spectrometry.  
Measurement of radiance underestimates nanoparticle binding within the tumor because NIR 
light scatters throughout deeper tissues in vivo. Since the fluorescence intensity values are 
determined from intact tissue and not homogenized tissue, it is possible that the fluorescence 
intensity is not homogeneously distributed in the tissue and thus the values may vary in different 
segments of the same tissue. In contrast, HPLC-MS analysis of tumor drug content reflects 
concentration values determined directly from tissue homogenates.98-100 While PET imaging can 
also be used along with scintigraphy of tissue homogenates to obtain radioactivity levels directly 
from tissues, this method requires careful handling and presents safety concerns due to 
radioactivity. HPLC-MS analysis circumvents limitations from both optical imaging by 
analyzing tissue homogenates, and those of PET imaging by providing a safer alternative to 
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radioactivity. In addition, HPLC-MS provides an analytical method for directly quantifying the 
actual drug or small molecule loaded within nanoparticle drug delivery systems, rather than 
indirect quantification via either an optical or radioactive imaging probe.98-100 The use of HPLC-
MS directly quantifies the content of chemotherapy drugs such as paclitaxel and camptothecin in 
tumors and other tissues.98-100 Like other mass spectrometry methods, it is a highly sensitive tool 
for validating and complementing tumor targeting data provided by NIR optical imaging 
methods. Combining both optical imaging and mass spectrometry techniques enables 
confirmation of results using both imaging and chemical analysis of nanoparticle drug delivery 
systems targeted to tumors.  
 
Summary 
Development of nanoparticles for drug delivery and improved conjugating methods make 
it possible to design and create multifunctional nanoparticles for tumor-targeted drug delivery.  
Multifunctional nanoparticles composed of biodegradable polymers can be used to deliver 
controlled release of therapeutic drugs, functionalized with imaging agents for diagnostic 
purposes, and tumor-specific ligands for targeting of cancer. In this work, biodegradable 
polymeric ‘nanosponges’ were used to optimize targeted delivery of paclitaxel and camptothecin 
to lung cancer. Chapter 2 explores the optimization of linear polyester copolymers via tin (II) 
triflate catalyzed ring opening polymerization of lactone monomers. These low polydispersity 
polyesters are then used to produce optimized nanosponges. Chapter 3 shows the effect of 
paclitaxel or camptothecin loaded nanosponges in various schedules for the  treatment of lung 
cancer cells in vitro. Chapter 4 discusses the synthesis of a cyclic RGD peptide targeted 
nanosponge for targeting and imaging in lung cancer cells. Chapter 5 explores the feasibility of 
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HVGGSSV peptide targeted nanosponges for targeting, imaging and treatment of lung cancer in 
an in vivo mouse model. Chapter 6 examines future directions and final conclusions from these 
works.  
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CHAPTER 2 
 
SYNTHESIS OF SECOND GENERATION POLYESTER ‘NANOSPONGES’ VIA 
RING-OPENING POLYMERIZATION WITH TIN (II) TRIFLATE CATALYST 
 
Abstract 
Nanoparticles made from biomedical polymers are commonly used in drug delivery 
applications because they allow delivery of drugs with degradation of nanocarriers over time. 
These polymers typically come from a class of aliphatic polyesters that are produced via ring-
opening polymerization of lactone monomers. While a large number of catalysts and initiators 
have been previously investigated in the literature for polymerization of lactones, the most 
common catalyst used for these applications is tin (II) octanoate. In order to produce a polymer 
with the desired reaction conditions and characteristics, catalyst selection plays a significant role. 
The aim of this study was to investigate tin (II) triflate as a catalyst for the ring-opening 
polymerization (ROP) of poly(VL-co-AVL) and poly(VL-co-AVL-co-OPD) copolymers. Both 
copolymers were prepared using tin (II) triflate and ethyl alcohol initiator, and results showed 
improved yields and monomer incorporation for both polymers, with narrower PDIs for 
poly(VL-co-AVL) copolymers compared to poly(VL-co-AVL-co-OPD) copolymers. Lower 
polydispersity in linear polymer precursors can translate into greater control and uniformity of 
resulting nanoparticle size distribution. This can in turn allow for more uniform drug release, 
making it easier to predict and control drug release profiles for nanoparticles both in vitro and in 
vivo. 
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Introduction 
Polymers for drug delivery 
Biomedical polymers typically used in drug delivery applications have mostly come from 
a class of aliphatic polyesters widely known for their superior biocompatible and biodegradable 
properties.7-9,52,53 Utilizing biodegradable materials has advantages for drug delivery applications 
because it allows delivery of drugs with degradation of the nanocarrier over time. Ideally, this 
material should degrade at a rate that is compatible with its purpose, and its degradation products 
should be non-toxic and physiologically compatible. 7-9,52,53 In addition, these materials should 
have mechanical properties (crystallinity, morphology, etc.) that are suitable for their intended 
applications. Polyesters are hydrolytically degraded, with ester bonds being broken over time at 
rates that can be controlled depending on the length of the polymer chains.4-6,10,12,14,51 Aliphatic 
polyesters have been used as scaffolds for drug delivery systems with sustained release of drugs 
and other small molecules, as sutures and adhesives, and in tissue engineering applications.7-
9,52,53 Examples of some commonly used polyesters include homopolymers and copolymers of 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(caprolactone) (PCL), 
poly(valerolactone) (PVL) and poly(butyrolactone) (PBL), among others (Figure 2.1).7-9,52,53 The 
resulting polymers are composed of lactide and lactone monomer repeat units bearing different 
functional groups, and are suitable for a variety of applications. By changing the type and ratio of 
monomers used, the composition of these polymers can be controlled and different chemical and 
mechanical properties can be produced for specific applications. Polymerizations of these 
monomers are also similar, allowing for many different combinations of copolymers to be 
produced. Consequently, aliphatic polyesters have been widely used to produce nanoparticles for 
drug delivery applications. 
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Ring-opening polymerization 
Ring-opening polymerization of lactone monomers are important in the development of 
aliphatic polyesters for drug delivery applications. This polymerization method offers the 
potential for preparing homopolymers and copolymers with defined molecular weight, chain 
length, and architecture. These polymers exhibit varying architectures from block and random 
linear copolymers to branched and dendritic structures. Various functional groups pendant on 
polymer backbones can be used to customize the physical and chemical properties of these 
polymers, such as their hydrophilicity and rate of degradation, as well as providing options for 
further chemical modification. Polymerization with allyl valerolactone (AVL) monomer provides 
the possibility of partial epoxidation of these allyl groups for nanoparticle formation using 
amine/epoxide chemistry. Polymerization with 2-oxepane-1, 5-dione (OPD) monomer provides 
additional polar oxygens for increased hydrophilicity of resulting polymers. The sequence of 
monomers in a linear polymer chain is also of consideration, as preparation of a copolymer with 
random monomer distribution (ABABBA) instead of block (AAABBB) provides additional 
amorphousness and decreases the crystallinity of the copolymer, increasing hydrophilicity and 
and rate of degradation. 
 
Material properties 
The hydrolytic degradation rate of a polymer depends primarily on its hydrophobicity and 
crystallinity, as these factors determine how well water molecules can penetrate the polymer.6-10 
Greater hydrophobicity reduces interaction with water molecules and slows down degradation. In 
general, polymers with higher crystallinity degrade slower than polymers with lower 
crystallinity, and polymers with more amorphous regions degrade faster than those with fewer 
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amorphous regions. One way to introduce more amorphous regions into a polymer is to use more 
than one monomer, and thus produce a copolymer. The presence of any sterically hindering 
functional groups at scission sites (where ester bonds are cleaved) also decreases the rate of 
degradation. 
 
 
Figure 2.1.  Commonly used cyclic ester monomers for ring-opening polymerization of 
polyesters. 
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Catalyst optimization 
A large number of catalysts and initiators have been previously investigated in the 
literature for polymerization of lactones.10,12,17,18,51 In order to produce a polymer with the 
desired reaction conditions and characteristics, catalyst selection plays a significant role. The aim 
of this study was to investigate tin (II) trifluoromethanesulfonate (tin triflate or Sn(OTf)2) as a 
catalyst for the ring-opening polymerization (ROP) of poly(VL-co-AVL) and poly(VL-co-AVL-
co-OPD) copolymers. 
Tin (II) bis-(2-ethylhexanoate), also known as tin octanoate or Sn(Oct)2, has been the 
most extensively used metal catalyst for preparation of polymers using ROP methods.15,16 
Because it exhibits lower sensitivity towards water, it is easier to use in the preparation of 
polymers industrially. It also has received approval by the Food and Drug Administration (FDA) 
for the formulation of polymer coatings used in many food packaging materials.4-6,15,16 However, 
high reaction temperatures (above 100 °C) are needed for its use in typical ROP methods, and 
resulting intermolecular and intramolecular esterification tend to produce polymers with wide 
polydispersities.10,12,17,18,51  This can be problematic if polymers of uniform chain length are 
required, such as in the preparation of polymer-based nanoparticles.  
The mechanism of initiation in tin triflate catalyzed polymerization of lactones is shown 
in Figure 2.2. 10-13,17,18,51  An initiating species (tin triflate initiator) is formed, followed by 
coordination-insertion of the monomer into the alkoxide bond produced, and then chain transfer 
of the active polymerizing center to remaining unreacted alcohol. 10-13,17,18,51   The coordination-
insertion reaction with the lactone monomer creates the first actively propagating linear polymer 
chain end. This chain end is composed from the initiating alcohol and the active propagating 
center (from the first monomer unit and tin alkoxide). 10-13,17,18,51   
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Figure 2.2. Ring-opening polymerization with tin (II) triflate catalyst.  
 
The use of triflates such as Sn(OTf)2, has been less frequent in the ROP methods for the 
preparation of polyesters. Due to its high sensitivity to moisture and other impurities, typical 
procedures require extensive purification of monomers prior to polymerization.4-6,10,12,14,51 High 
reactivity coupled with the presence of any impurities can produce bimodal polymers that require 
further purification.  
In this study, we sought to use tin (II) triflate catalysed ROP of δ-valerolactone (VL), α-
allyl(valerolactone) (AVL), and 2-oxepane-1,5-dione (OPD) monomers to produce linear 
polyesters of narrow polydispersity. The resulting random copolymers were then used as 
scaffolds for production of cross-linked ‘nanosponges’ for delivery of chemotherapeutics. In 
order to optimize the linear polymers produced, reaction conditions including catalyst selection 
were first studied and optimized to produce well-defined polymers with narrow polydispersity 
and predictable incorporation of lactones with various functionalities.  
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Experimental 
Materials and Methods 
Reagents.  Chemical reagents were purchased from Sigma-Aldrich and Strem Chemicals, and 
used as received unless otherwise stated.  
NMR Spectroscopy.  All 1H NMR spectra were acquired using a 400 MHz Bruker AV-400 NMR 
with deuterated chloroform (CDCl3) and tetramethylsilane as internal standard.  
Purification. Biotage Isolera Spektra One flash purification system equipped with a UV λ 
absorbance detector (254 nm) was used to purify AVL monomers. Purification was performed 
using a SNAP HP 50 g silica column with a 5-20% ethyl acetate gradient in n-hexanes with a 
flow rate of 50 ml/min. All monomers (AVL and VL) were vacuum distilled using a Kugelrohr 
distillation apparatus (Sigma Aldrich). 
Gel-permeation chromatography (GPC). All GPC was performed using a Waters 
chromatography system equipped with refractive index and dual λ absorbance detectors, four 5 
mm Waters columns (300 mm x 7.7 mm) with pore size (100, 1000, 100,000 and 1,000,000 Å 
respectively). All samples were dissolved in tetrahydrofuran (THF) or dimethylformamide 
(DMF), with a 20 µl injection volume and 1 mL/min flow rate. 
Transmission electron microscopy (TEM). TEM imaging was performed on nanoparticles by 
dissolving approximately 5 mg in a solution of 1 : 0.4 mL isopropanol/acetonitrile. The dissolved 
nanoparticles were sonicated for 5 minutes and stained with 4 drops of a 3% phosphotungstic 
acid/water solution for 10 minutes. This solution was sonicated once more for 5 minutes before 
the copper grids were prepared. Ultrathin Carbon Type-A 400 mesh copper grids (Ted Pella, 
Redding, CA) were gently immersed into the stained nanoparticle solution and allowed to dry for 
2 hrs prior to analysis. A 200 kV Philips CM20T transmission electron microscope was used to 
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acquire micrographs of the nanoparticles. 
δ-valerolactone monomer (VL) 
Technical grade δ-valerolactone was Kugelrohr distilled to produce a colorless liquid product.  
Synthesis of allyl-substituted valerolactone monomer (AVL) 
 
A flame dried 500 mL two-necked round bottom flask was equipped with a stir bar, sealed with a 
rubber septum, and purged with nitrogen for 30 min. To the flask, 156.25 mL of anhydrous THF 
was added and cooled to -78 °C in a dry ice/acetone bath. Following this, a basic solution of 
lithium diisopropylamine was produced by adding redistilled n,n-diisopropylamine (3.3 mL, 
23.63 mmol) and n-butyl lithium (2.5 M in hexanes) (9.35 mL, 23.38 mmol) dropwise via 
syringe. This solution was stirred for 20 minutes. A nitrogen purged solution of distilled δ-
valerolactone 1 (1.97 mL, 21.23 mmol) in anhydrous THF (56 mL) was then added dropwise via 
syringe over 30 min. After an additional 30 min of stirring, a nitrogen purged solution of allyl 
bromide (2.21 mL, 25.54 mmol) in hexamethylphosphoramide (4.43 mL, 25.46 mmol) was 
added via syringe. The reaction mixture was warmed up to -40 ºC and stirred for 2 hrs. The 
reaction was quenched with excess NH4Cl solution. The crude product was concentrated via 
rotary evaporator, washed three times with saturated NaCl solution, and dried with anhydrous 
MgSO4. The crude product was purified via column chromatography (Biotage Isolera), analyzed 
by thin layer chromatography and Kugelrohr distilled. Chromatography with a gradient of 5-20% 
ethyl acetate in n-hexanes as eluent gave a yellow liquid product. Kugelrohr distillation produced 
a colorless liquid product. Yield: 3.56 g (89%). 1H NMR (400MHz, CDCl3/TMS, ppm) δ: 5.82 
(m, 1H, H2C=CH-), 5.11 (m, 2H, H2C=CH-), 4.32 (m, 2H, -C(O)OCH2-), 2.60 (m, 2H, 
H2C=CHCH2-), 2.34 (m, 1H, H2C=CHCH2CH-), 2.08 (m, 1H, H2C=CHCH2CHCH2-), 1.92 (m, 
2H, C(O)OCH2CH2-), 1.57 (m, 1H, H2C=CHCH2CHCH2-).   
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Synthesis of 2-oxepane-1,5-dione monomer (OPD) 
To a 200 mL round bottom flask, equipped with stir bar, 1,4-cyclohexanedione (4.0 g, 35.84 
mmol) and 3-chloroperoxybenzoic acid (4.5 g, 55.35 mmol) was added. Reagents were dissolved 
in dichloromethane (44 mL) and the reaction mixture was stirred and refluxed for 6 h at 44 ºC in 
an oil bath. The reaction mixture was cooled to room temperature and solvent was removed via 
rotary evaporation. The crude product was washed five times with cold diethyl ether and dried 
under vacuum for 72 hrs. Isolated yield: 2.1g. 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: 4.41 (t, 
J = 5.2 Hz, 2H, -C(O)OCH2CH2C(O)-), 2.81 (m, 4H,  -CH2C(O)CH2-), 2.74 (m, 2H, -
CH2C(O)O-), 2.69 (m, 2H, -CH2C(O)-).  
 
 
Copolymerization of α-allyl-δ-valerolactone (AVL) 2 and δ-valerolactone (VL) 1. 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed with 
rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in anhydrous 
tetrahydrofuran was prepared (1.7 M) in a 50 mL flame dried and nitrogen purged round bottom 
flask, and a stock solution of Sn(OTf)2 catalyst in anhydrous tetrahydrofuran was prepared 
(3.7x10-2 M) in a 10 mL flame dried and nitrogen purged round bottom flask.  Ethanol (584 µL, 
1.0 mmol) and Sn(OTf)2 (261 µL, 9.64 x 10-6 mol) were added via syringe to the 25 mL 3-neck 
round bottom flask and the catalyst/initiator solution was allowed to stir at room temperature for 
30 minutes prior to simultaneous addition of δ-valerolactone (2.22 g, 22.0 mmol) and α-
allyl(valerolactone) (0.777 g, 5.548 mmol) monomers via syringe.  After addition of both 
monomers, the reaction was stirred for 24 h at room temperature. The resulting polymer was 
diluted with 1 mL anhydrous THF and purified by dropwise addition into 1 L of chilled methanol 
to remove any remaining monomer and catalyst. The methanol was decanted and the precipitate 
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redissolved in methylene chloride, rotary evaporated and dried in vacuo. The resulting polymer 
was observed as a waxy white solid.  Mw = 3000 Da; 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: 
5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 (m, -CH2-O-), 3.64 (m, CH3CH2O-), 2.34 (m, vl, -
CH2CH2C(O)O-, avl, H2C=CHCH2CH-, H2C=CHCH2CH-), 1.68 (m, avl and vl, -CHCH2CH2-), 
1.26 (t, CH3CH2O-). 
 
Partial epoxidation of poly(VL-co-AVL) 5 
In a 100 mL round bottom flask, equipped with stir bar and rubber septum, a solution of 
poly(VL-co-AVL) (1.0 g, 1.55 x 10-3 mol) was dissolved in 8.5 mL of methylene chloride. To 
this solution, meta-chloroperoxybenzoic acid (121.25 mg, 7.03 x 10-4 mol) was added. The 
solution was stirred for 24 hrs at room temperature and then concentrated via rotary evaporator. 
The crude product was dissolved in a minimal amount of dichloromethane (2 mL) and 
precipitated into an Erlenmeyer flask containing 500 mL cold diethyl ether. The solution was 
decanted, and the white solid was rotary evaporated and dried in vacuo to obtain the final white 
waxy polymer. Yield: 0.768 g (76.8%). 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: Decrease in 
allylic protons at 5.7 and 5.09 ppm and the appearance of small broad resonance peaks at 2.96, 
2.75 and 2.47 ppm due to the formation of the epoxide. Same method used for partial 
epoxidation of poly(VL-co-AVL-co-OPD) copolymer (6).   
 
Formation of nanoparticles using intermolecular crosslinking  
In a 250 mL round bottom flask equipped with stir bar and reflux condenser, a solution of 2,2'-
(ethylenedioxy)diethylamine (10.5 µL, 7.18x10-5 mol) in 29.55 mL methylene chloride was 
heated at 45 °C. A solution of poly(VL-co-AVL-co-EVL), (0.200 g, Mw = 3000 Da) dissolved in 
methylene chloride was added. The mixture was refluxed at 45 ºC for 12 hrs. Residual diamine 
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crosslinker was removed via dialysis against methylene chloride with Spectra/Por Dialysis 
Tubing (MWCO = 10,000). 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: Decrease in number of 
epoxide protons at 2.96, 2.75 and 2.47 ppm and the appearance of signals at 3.5 and 2.89 ppm 
corresponding to the protons near the secondary amine of the diamine crosslinker after the 
reaction. Same method used for formation of nanosponges from poly(VL-co-AVL-co-OPD-co-
EVL) copolymer.   
 
Results and Discussion 
In order to produce polyester-based nanoparticles for drug delivery, linear random 
copolymer precursors were first synthesized from lactone monomers. These lactone monomers 
include δ-valerolactone, α-allyl-δ-valerolactone, and 2-oxepane-1,5-dione. Scheme 2.1 shows the 
synthesis of α-allyl-δ-valerolactone (2) from commercially available δ-valerolactone (1). The 
availability of an allyl functional group presents an opportunity for further modifications. The 
synthesis of this monomer involves the formation of an enolate from δ-valerolactone, prior to 
nucleophilic attack by allyl bromide resulting in the allyl substituted δ-valerolactone. This 
monomer product was purified by column chromatography and Kugelrohr distilled in an 89% 
yield. Figure 2.3 shows a proton NMR of the resulting product, with signals (f, g, h) 
corresponding to the allyl group in the monomer.  
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Synthesis of Allyl-Substituted Valerolactone Monomer using Allyl Bromide 
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Scheme 2.1. Synthesis of α-allyl-δ-valerolactone monomer (AVL) (2).  
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Figure 2.3. 1H NMR of α-allyl-δ-valerolactone monomer in CDCl3. 
 
Synthesis of 2-oxepane-1,5-dione (4) monomer from commercially available 1,4-
cyclohexanedione (3) is shown in scheme 2.2. This single step synthesis involves the Baeyer-
Villiger oxidation of 1,4-cyclohexanedione with m-CPBA to produce a cyclic ester with an 
additional oxygen. This product was purified by filtration with a yield of 53%. Figure 2.4 shows 
a proton NMR of the resulting monomer product. 
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Synthesis of 2-oxepane-1,5-dione monomer  
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Scheme 2.2. Synthesis of 2-oxepane-1,5-dione monomer (OPD) (4).  
 
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 ppm
2.
69
38
2.
70
77
2.
72
39
2.
74
93
2.
78
29
2.
80
72
2.
81
30
2.
82
69
2.
83
85
4.
40
29
4.
41
57
4.
42
90
4.
59
60
4.
61
05
4.
62
50
3.
15
1.
00
0.
09
a 
c,b,d 
O
O
O
a
b
c
d
 
 
Figure 2.4. 1H NMR of 2-oxepane-1,5-dione monomer in CDCl3. 
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Linear random copolymers of these monomers (VL, AVL and OPD) were then produced 
using ring-opening polymerization (ROP) with ethyl alcohol as an initiator. Previously, Sn(Oct)2 
was used as a catalyst for the ROP of these monomers, however, since linear polymer precursors 
of narrower polydispersity were desired, Sn(OTf)2 was investigated as an alternative catalyst. 
The ROP copolymerization of VL (1) and AVL (2) using ethyl alcohol initiator led to the 
formation of poly(VL-co-AVL) copolymer (5), when in the presence of Sn(OTf)2 catalyst at 25 
°C for 24 hrs. Figure 2.6b shows a table of representative results from six reactions performed. 
These results show that copolymers of narrow polydispersity were produced with PDIs as low as 
1.06, and a single narrow symmetrical peak as shown in the GPC chromatogram (figure 2.6c). 
Incorporation of the AVL monomer into the copolymer product ranged from 55.7% to 81.4%. 
Overall yields for this copolymer varied from 44.5% to as high as 94.0%. The molecular weights 
(Mw) were calculated based on proton NMR, and were in the range expected. Figure 2.5 shows a 
proton NMR of the poly(VL-co-AVL) copolymer (5), with signals (m, n, o) corresponding to the 
allyl functional group from the AVL (2) monomer. 
 
Copolymerization of α-allyl-δ-valerolactone (AVL) 2 and δ-valerolactone (VL) 1. 
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Scheme 2.3. Preparation of poly(VL-co-AVL) copolymer with Sn(OTf)2 (5).  
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Figure 2.5. 1H NMR of poly(VL-co-AVL) linear polymer in CDCl3. 
 
The ROP copolymerization of VL (1), AVL (2) and OPD (4) using ethyl alcohol initiator 
led to the formation of poly(VL-co-AVL-co-OPD) copolymer (6), when in the presence of 
Sn(OTf)2 catalyst at 25 °C for 24 hrs. Figure 2.9b shows a table of representative results from 
five reactions performed. These results show that copolymers were produced with a range in PDI 
from 1.30-1.35, but with a single wider symmetrical peak as shown in the GPC chromatogram 
(figure 2.9c). These copolymers are of wider polydispersity than copolymer (5) made without the 
use of OPD monomer. Incorporation of the OPD monomer into the copolymer product was much 
higher than the AVL monomer, and ranged from 89.0% to 98.8%. Overall yields for this 
copolymer varied from 76.3% to 90.0%. The molecular weights (Mw) were calculated based on 
proton NMR, and were in the range expected.  
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Preparation of poly(VL-co-AVL) copolymer 
!
Copolymer % allyl incorporation 
% 
yield PDI 
Mw 
(kg/mol) 
Reaction 
Time (hrs) 
1 65.5% 44.5 1.07 2.17 18 
2 61.9% 93.8 1.18 2.74 21 
3 80.4% 56.8 1.06 2.07 18 
4 81.4% 60.2 1.12 2.34 22 
5 65.3% 87.5 1.06 4.64 21 
6 55.7% 94.0 1.07 4.76 21 !
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Figure 2.6. Characterization of poly(VL-co-AVL) linear copolymer. (A) Scheme for the ring-
opening polymerization reaction of AVL and VL monomers using tin (II) triflate catalyst and its 
linear copolymer product. (B) Table showing % allyl incorporation from 1H NMR, % yield, 
polydispersity from GPC, Mw from 1H NMR, and reaction time. (C) GPC trace and (D) 1H NMR 
spectra in CDCl3.  
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Copolymerization of 2-oxepane-1,5-dione (OPD) 4, α-allyl-δ-valerolactone (AVL) 2 and δ-
valerolactone (VL) 1. 
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Scheme 2.4. Preparation of poly(VL-co-AVL-co-OPD) copolymer with Sn(OTf)2 (6).   
 
Partial epoxidation of allyl groups from these linear copolymers converts some of the 
allyl groups to epoxides, while maintaining the rest for further modifications after nanoparticle 
formation. Scheme 2.5 shows the partial epoxidation of allyl groups in (3) to epoxides in (7). The 
epoxidation of the double bond from the allyl was performed using m-CPBA, and produced the 
epoxidized product in a 76.8% yield. Figure 2.7 and 2.8 show a proton NMR of the resulting 
copolymer (7) product with a reduction in the signals corresponding to the allyl groups (l, m, n) 
and the appearance of new signals arising from the epoxide groups (t, u).  
 
Partial epoxidation of poly(VL-co-AVL) 5 
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Scheme 2.5. Preparation of poly(VL-co-AVL-co-EVL) copolymer (7). 
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Figure 2.7. 1H NMR of poly(VL-co-AVL-co-EVL) precursor in CDCl3. 
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Figure 2.8. Characterization of poly(VL-co-AVL-co-EVL) copolymer. (A) Scheme for the 
partial epoxidation of allyl groups from its poly(VL-co-AVL) copolymer precursor (3). (B) 1H 
NMR spectrum in CDCl3 for the poly(VL-co-AVL) copolymer precursor, showing 10.25% allyl 
groups. (C) 1H NMR spectra in CDCl3 for the resulting poly(VL-co-AVL-co-EVL) copolymer 
showing conversion of 5.4% of the original allyl groups to epoxides, leaving 5.9% of the original 
allyl groups. 
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Preparation of poly(VL-co-AVL-co-OPD) copolymer 
 
Copolymer % OPD incorporation 
% 
yield PDI 
Mw 
(kg/mol) 
Reaction 
Time (hrs) 
1 92.0% 79.2 1.33 3.4 24 
2 98.8% 84.5 1.34 2.8 24 
3 89.0% 79.2 1.35 2.0 24 
4 96.0% 90.0 1.34 4.9 24 
5 95.0% 76.3 1.30 2.4 24 !
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Figure 2.9. Characterization of poly(VL-co-AVL-co-OPD) linear copolymer. (A) Scheme for 
the ring-opening polymerization reaction of OPD, AVL and VL monomers using tin (II) triflate 
catalyst and its linear copolymer product. (B) Table showing % OPD incorporation from 1H 
NMR, % yield, polydispersity from GPC, Mw from 1H NMR, and reaction time. (C) GPC trace 
and (D) 1H NMR spectra in CDCl3.  
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Nanoparticles were formed from these partially epoxidized copolymers using an 
intermolecular crosslinking process as shown in scheme 2.6 and figure 2.11. These copolymers 
have both pendant allyl and epoxide groups, which can be used for various modifications. The 
epoxide groups are reacted with primary terminal amines from a crosslinker, while refluxing in 
dichloromethane for 12 hrs. By adjusting the ratio of amines to epoxides, the crosslinking density 
of the nanoparticle can be tailored to produce varying degradation and drug release rates. These 
nanoparticles are then purified by dialysis in dichloromethane. Figure 2.10 shows a proton NMR 
of nanoparticles formed from copolymer (7), with a decrease in the number of epoxide protons 
(between 2.5 - 3 ppm) and the appearance of new signals near 3.5 ppm (l-u) corresponding to the 
protons near the secondary amine from the crosslinker after completion of the reaction. Figure 
2.11 shows the entire process for the formation of nanoparticles from lactone monomers. 
 
 
Formation of nanoparticles using intermolecular crosslinking  
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Scheme 2.6. Synthesis of poly(VL-co-AVL-co-EVL) nanoparticles.  
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Figure 2.10. 1H NMR of nanoparticles in DMSO-d6.  
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Figure 2.11. Diagram of ‘nanosponge’ formation via intermolecular crosslinking of poly(VL-co-
AVL) linear copolymers with a diamine crosslinker. 
 
	   49	  
Characterization of intermolecularly cross-linked nanoparticles 
Nanoparticles were characterized by TEM to analyze size and morphology.  Figure 2.12 below 
shows nanoparticles prepared from both poly(VL-co-AVL-co-EVL) and poly(VL-co-AVL-co-
OPD-co-EVL) copolymers partially oxidized to produce 5% epoxyvalerolactone (EVL) units. 
TEM analysis shows nanoparticles of spherical shape with uniform staining. Figure 2.12 shows a 
representative image taken at 3800x magnification illustrating the distribution of sizes for a 
typical batch of nanoparticles.  
! !
!" #"
 
Figure 2.12. Size characterization of nanosponges made from tin (II) triflate. TEM micrographs 
and histograms of (A) poly(VL-co-AVL-co-EVL) nanosponges (left) and (B) poly(VL-co-AVL-
co-EVL- co-OPD) nanosponges (right). Scale bar shows 100 nm. 
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Differential scanning calorimetry analysis of poly(VL-co-AVL-co-EVL) and poly(VL-
co-AVL-co-EVL- co-OPD) nanoparticles was performed to evaluate amorphousness (Figure 
2.13). Lower crystallization and melting temperatures were observed with increasing % OPD. 
All three samples show glass transition temperatures between -50 to -57.5°C, indicating that at 
physiological temperatures they are amorphous, making them suitable for in vivo applications. 
!
Nanoparticle %OPD Tg (°C) Tc (°C) Tm (°C) 
1 0 -57.5 15 50 
2 3 -52.5 5 45 
3 7 -50 -15 45 !
!"
#"
   
 
Figure 2.13. DSC analysis of poly(VL-co-AVL-co-EVL- co-OPD) nanosponges showing (A) 
heat flux as a function of temperature. (B) Nanosponges with increasing % OPD at the glass 
transition temperature (Tg), crystallization temperature (Tc) and melting temperature (Tm). 
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Conclusion 
Use of tin (II) triflate catalyst for ring opening polymerization of lactones is feasible and 
produces copolymers of narrow PDI with high incorporation of AVL and OPD. Copolymers of 
poly(VL-co-AVL) and poly(VL-co-AVL-co-OPD) were prepared and results showed better 
incorporation of OPD monomer (89-98.8%) in poly(VL-co-AVL-co-OPD) compared to AVL 
monomer (55.7-81.4%) in poly(VL-co-AVL). However, these polymers also showed slightly 
broader PDI (1.3-1.35) compared to copolymers without OPD (1.06-1.18). PDI increased with 
presence of OPD, suggesting that the inclusion of this monomer in high quantities creates less 
uniform polymer chains and a broader distribution of chain lengths. Since this monomer is more 
polar and hydrophilic, it is possible that it attracts more moisture than the other monomers and 
this causes greater chain scission, creating a wider distribution of polymer chain lengths.  
Reaction conditions for such tin (II) triflate polymerizations are preferable over those of 
tin (II) octanoate catalysts, with reactions proceeding at room temperature to completion in under 
24 hrs compared to temperatures over 100 °C and 48 hrs. These improved conditions are not 
only more convenient for laboratory preparation of polyesters, they also provide improved 
yields, and improved monomer incorporation, resulting in greater efficiency per reaction. In 
addition, narrower polydispersities as achieved with tin (II) triflate compared to tin (II) octanoate 
produce more uniform polymer chains, which in turn translates to greater control and uniformity 
of nanoparticle size distribution. This is significant for in vivo applications because nanoparticles 
must remain under 200 nm in order to be compatible with physiological limitations (embolisms, 
immune response, etc.).  In addition, greater uniformity of nanoparticle size distribution also 
allows for more uniform drug release, making it easier to predict and control drug release 
profiles for nanoparticles both in vitro and in vivo. 
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CHAPTER 3 
 
NANOSPONGE DRUG ENCAPSULATION, RELEASE AND 
IN VITRO CELL STUDIES 
 
Abstract 
Development of nanoparticle drug delivery systems has allowed greater control over drug 
release and Despite these advances, however, solubilization of drugs and tailoring drug dosage 
remains a challenge.2,3 To address these concerns, biodegradable drug carriers have been 
investigated and developed for targeting and release of hydrophobic drugs in a controlled 
manner.4-6 In particular, ‘nanosponges’ are well suited for these applications due to their 
biodegradable polyester-based nano-network, composed of a cross-linked 3-dimensional 
scaffold. These nanoparticles can be produced in different sizes and crosslinking densities, and 
can be functionalized with tumor targeting units and imaging agents for visualization in vivo.7-9  
Hydrophobic drugs can be loaded into these nanoparticles, producing readily injectable 
formulations with linear sustained drug release.8  
This study investigated the feasibility of using nanosponge encapsulated paclitaxel and 
camptothecin to determine the optimum drug combination and sequence for treating lung cancer. 
Here, the role of drug combination and sequence in vitro, in both mouse and human lung cancer 
cell lines, was investigated using synthesized nanosponges loaded with either paclitaxel (NP 
PTX) or camptothecin (NP CPT). Results showed not only that paclitaxel and camptothecin 
combination therapy produced the greatest G2/M phase arrest compared to monotherapy, but 
also that sequential administration of NP PTX followed by NP CPT further enhanced caspase-
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dependent cell death compared to simultaneous administration. Paclitaxel, more so than 
campthothecin, was observed to drive cells into G2/M phase arrest and subsequent apoptosis. 
Further studies are necessary to determine the molecular basis for this effect in lung cancer. 
Sequential administration (NP PTX → NP CPT) of nanoparticle drug delivery systems resulted 
in greater cell death and decreased cell proliferation. Collectively, these studies suggest that dual 
combination treatment with administration of paclitaxel prior to camptothecin produces greater 
G2/M phase arrest, microtubule aggregation, cell death and reduced proliferation compared to 
simultaneous and monotherapy treatment. 
 
Introduction 
Drug delivery systems The	   development	   of	   targeted	   drug	   delivery	   systems	   has	   allowed	   cytotoxic	  chemotherapeutics	   to	   be	   administered	   selectively	   to	   malignant	   tumors	   while	   sparing	  healthy	   tissues	   from	   undesirable	   side	   effects.1-­‐6,15	   Despite	   these	   advances,	   however,	  solubilization	  of	  drugs	  and	  tailoring	  drug	  dosage	  remains	  a	  challenge.2,3	  To	  address	  these	  concerns,	  biodegradable	  drug	  carriers	  have	  been	  investigated	  and	  developed	  for	  targeting	  and	   release	   of	   hydrophobic	   drugs	   in	   a	   controlled	  manner.4-­‐6	   In	   particular,	   ‘nanosponges’	  are	   well	   suited	   for	   these	   applications	   due	   to	   their	   biodegradable	   polyester-­‐based	   nano-­‐network,	   composed	   of	   a	   cross-­‐linked	   3-­‐dimensional	   scaffold.	   These	   nanoparticles	   can	   be	  produced	   in	   different	   sizes	   and	   crosslinking	   densities,	   and	   can	   be	   functionalized	   with	  tumor	   targeting	  units	   and	   imaging	  agents	   for	  visualization	   in	  vivo.7-­‐9	   	  Hydrophobic	  drugs	  can	   be	   loaded	   into	   these	   nanoparticles,	   producing	   readily	   injectable	   formulations	   with	  linear	  sustained	  drug	  release.8	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Drug combinations 
The potential of sequential combination drug delivery using these targeted nanocarriers is 
investigated using mitotic inhibitors and topoisomerase I inhibitors, in addition to establishing 
tumor targeting of these nanosponges with the HVGGSSV peptide. Paclitaxel (Taxol®) has 
shown promise as a chemotherapeutic alone and in combination with other drugs such as 
camptothecin in the treatment of a variety of cancers.14-16,33 As a mitotic inhibitor, its main 
mechanism of action involves the stabilization of microtubules and G2/M phase cell cycle arrest 
(Figure 3.1), disruption of mitosis, and apoptosis.14,15  
 
 
M 
Mitosis 
 
G1 
Preparation 
for synthesis 
 
S 
DNA 
replication 
 
 
G2 
Preparation 
for mitosis 
 
 
 
Figure 3.1.  Phases of the cell cycle: G1 (growth phase 1) preparation for DNA synthesis (6-12 
hrs), S phase DNA synthesis (6-8 hrs), G0 (not shown above) resting state, G2 (growth phase 2) 
preparation for mitosis (3-4 hrs), and M phase shows mitosis or cell division (1 hr). 
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Camptothecin is a topoisomerase I inhibitor that causes DNA damage by reversibly 
stabilizing the covalent enzyme-DNA intermediate, causing DNA double strand breaks, S/G2 
cell cycle arrest (Figure 3.1) and apoptosis.16-19,22,23,34,37 Despite its potency, the use of 
camptothecin in the clinic has been limited greatly due to its poor water solubility, toxicity and 
side effects. While analogues of camptothecin, such as Irinotecan and Topotecan, have been 
developed to enhance water solubility, toxicity still remains a limiting side effect.20 Seliciclib 
(roscovitine) is a small molecule cyclin-dependent kinase (CDK) inhibitor whose main 
mechanism of action involves the preferential inhibition of CDK2, 7 and 9.38-40,31 These CDKs 
affect the growth phase of the cell cycle by coordinating the division of cells in an accurate and 
timely manner (Figure 3.1). Disruption of their activation thus serves as a useful way to inhibit 
the growth and proliferation of cancer cells.38-40,31 While not as hydrophobic a drug as paclitaxel 
and camptothecin, seliciclib can still benefit from nanoparticle technology as it can deliver 
greater concentrations of drug to tumors.  
Targeted drug delivery systems that provide sustained release of highly hydrophobic 
small molecules specifically at tumor sites exhibit particular promise for combination 
chemotherapy, where delivery of lower doses for extended times can help enhance efficacy and 
reduce toxicity. Moreover, continuous low doses of drug over time (metronomic chemotherapy), 
also allows for greater anti-angiogenic efficacy.21 Biodegradable targeted nanosponges with a 
cross-linked polymeric architecture create controlled low dose drug release profiles that are 
highly suitable for this application. In this chapter, the optimal dual drug combination and 
treatment schedule are determined for drug-loaded nanoparticles using in vitro assays in lung and 
prostate cancer cell lines. These results are then used in chapter 5 to investigate effects in an in 
vivo lung cancer model.  
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Experimental 
Materials and Methods 
Reagents.  Chemical reagents were purchased from Sigma-Aldrich and Strem Chemicals, and 
used as received unless otherwise stated. Chemotherapeutic drugs from LC Laboratories. 
Peptides (GCGGGNHVGGSSV) were purchased from EZBiolab Inc. (Carmel, IN). Spectra/Por® 
Dialysis membrane (MWCO=10,000) in 0.05% sodium azide was purchased from Spectrum 
Laboratories. SnakeSkin® Pleated Dialysis Tubing, regenerated cellulose, was purchased from 
Pierce Biotechnology.  
 
Preparation of Monomers 
δ-valerolactone monomer (VL) 
Technical grade δ-valerolactone was Kugelrohr distilled to produce a colorless liquid product.  
α-allyl-δ-valerolactone monomer (AVL) 
A flame dried 500 mL two-necked round bottom flask was equipped with a stir bar, sealed with a 
rubber septum, and purged with nitrogen for 30 min. To the flask, 156.25 mL of anhydrous THF 
was added and cooled to -78 °C in a dry ice/acetone bath. Following this, a basic solution of 
lithium diisopropylamine was produced by adding redistilled n,n-diisopropylamine (3.3 mL, 
23.63 mmol) and n-butyl lithium (2.5 M in hexanes) (9.35 mL, 23.38 mmol) dropwise via 
syringe. This solution was stirred for 20 minutes. A nitrogen purged solution of distilled δ-
valerolactone (1.97 mL, 21.23 mmol) in anhydrous THF (56 mL) was then added dropwise via 
syringe over 30 min. After an additional 30 min of stirring, a nitrogen purged solution of allyl 
bromide (2.21 mL, 25.54 mmol) in hexamethylphosphoramide (4.43 mL, 25.46 mmol) was 
added via syringe. The reaction mixture was warmed up to -40 ºC and stirred for 2 hrs. The 
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reaction was quenched with excess NH4Cl solution. The crude product was concentrated via 
rotary evaporator, washed three times with saturated NaCl solution, and dried with anhydrous 
magnesium sulfate. The crude product was purified via column chromatography (Biotage 
Isolera), analyzed by thin layer chromatography and Kugelrohr distilled. Chromatography with a 
gradient of 5-20% ethyl acetate in n-hexanes as eluent gave a yellow liquid product. Kugelrohr 
distillation produced a colorless liquid product. Yield: 3.56 g (89%). 1H NMR (400MHz, 
CDCl3/TMS, ppm) δ: 5.7 (m, 1H, H2C=CH-), 5.08 (m, 2H, H2C=CH-), 4.28 (m, 2H, -
C(O)OCH2-), 2.53-2.58 (m, 2H, H2C=CHCH2-), 2.27 (m, 1H, H2C=CHCH2CH-), 2.06 (m, 1H, 
H2C=CHCH2CHCH2-), 1.89 (m, 2H, C(O)OCH2CH2-), 1.55 (m, 1H, H2C=CHCH2CHCH2-). 
Preparation of Linear Polymer Precursors 
Poly(VL-co-AVL) from Sn(OTf)2 catalyst 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed with 
rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in anhydrous 
tetrahydrofuran was prepared (1.7 M) in a 50 mL flame dried and nitrogen purged round bottom 
flask, and a stock solution of Sn(OTf)2 catalyst in anhydrous tetrahydrofuran was prepared 
(3.7x10-2 M) in a 10 mL flame dried and nitrogen purged round bottom flask.  Ethanol (584 µL, 
1.0 mmol) and Sn(OTf)2 (261 µL, 9.64 x 10-6 mol) were added via syringe to the 25 mL 3-neck 
round bottom flask and the catalyst/initiator solution was allowed to stir at room temperature for 
30 minutes prior to simultaneous addition of δ-valerolactone (2.22 g, 22.0 mmol) and α-
allyl(valerolactone) (0.777 g, 5.548 mmol) monomers via syringe.  After addition of both 
monomers, the reaction was stirred for 24 hrs at room temperature. The resulting polymer was 
diluted with 1 mL anhydrous THF and purified by dropwise addition into 1 L of chilled methanol 
to remove any remaining monomer and catalyst. The methanol was decanted and the precipitate 
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dissolved in methylene chloride, rotary evaporated and dried in vacuo. The resulting polymer 
was observed as a waxy white solid.  Mw = 3000 Da; PDI = 1.09; 1H NMR (400 MHz, 
CDCl3/TMS, ppm) δ: 5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 (m, -CH2-O-), 3.64 (m, 
CH3CH2O-), 2.34 (m, vl, -CH2CH2C(O)O-, avl, H2C=CHCH2CH-, H2C=CHCH2CH-), 1.68 (m, 
avl and vl, -CHCH2CH2-), 1.26 (t, CH3CH2O-). 
Poly(VL-co-AVL) from Sn(Oct)2 catalyst 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed with 
rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in anhydrous 
tetrahydrofuran was prepared (1.7 M) in a 25 mL flame dried and nitrogen purged round bottom 
flask, and a stock solution of Sn(Oct)2 catalyst in anhydrous tetrahydrofuran was prepared in a 10 
mL flame dried and nitrogen purged round bottom flask. Ethanol (360 µL, 6.14 x10-1 mol) and 
Sn(Oct)2 (330 µL, 1.22 x 10-2 mol) were added via syringe to the 50 mL 3-neck round bottom 
flask and the catalyst/initiator solution was allowed to stir at room temperature for 30 minutes 
prior to simultaneous addition of δ-valerolactone (2.46 g, 28.53 x 10-3  mol) and α-
allyl(valerolactone) (0.93 g, 7.134 x 10-3 mol) monomers via syringe.  After addition of both 
monomers, the reaction was stirred for 48 hrs at 105 °C in an oil bath. The resulting polymer was 
diluted with 1 mL methylene chloride and purified by dropwise addition into 1.5 L of chilled 
diethyl ether to remove any remaining monomer and catalyst. The ether was decanted and the 
precipitate dissolved in methylene chloride, rotary evaporated and dried in vacuo. The resulting 
polymer was observed as a viscous yellow liquid.  1H NMR (300 MHz, CDCl3/TMS, ppm) δ: 
5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 (m, -CH2-O-), 3.64 (m, CH3CH2O-), 2.34 (m, vl, -
CH2CH2C(O)O-, avl, H2C=CHCH2CH-, H2C=CHCH2CH-), 1.68 (m, avl and vl, -CHCH2CH2-), 
1.26 (t, CH3CH2O-). 
	   64	  
Poly(VL-co-AVL-co-EVL) 
In a 100 mL round bottom flask, equipped with stir bar and rubber septum, a solution of 
poly(VL-co-AVL) (1.0 g, 1.55 x 10-3 mol) was dissolved in 8.5 mL of methylene chloride. To 
this solution, meta-chloroperoxybenzoic acid (121.25 mg, 7.03 x 10-4 mol) was added. The 
solution was stirred for 24 hrs at room temperature and then concentrated via rotary evaporator. 
The crude product was dissolved in a minimal amount of dichloromethane (2 mL) and 
precipitated into an Erlenmeyer flask containing 500 mL cold diethyl ether. The solution was 
decanted, and the white solid was rotary evaporated and dried in vacuo to obtain the final white 
waxy polymer. Yield: 0.768 g (76.8%). 1H NMR (400MHz, CDCl3/TMS, ppm) δ: Decrease in 
allylic protons at 5.7 and 5.09 ppm and the appearance of small broad resonance peaks at 2.96, 
2.75 and 2.47 ppm due to the formation of the epoxide.  
Formation of nanosponges 
In a 250 mL round bottom flask equipped with stir bar and reflux condenser, a solution of 2,2'-
(ethylenedioxy) diethylamine (10.5 µL, 7.18x10-5 mol) in 29.55 mL methylene chloride was 
heated at 45 °C. A solution of poly(VL-co-AVL-co-EVL), (0.200 g, Mw = 3000 Da) dissolved in 
methylene chloride was added. The mixture was refluxed at 45 ºC for 12 hrs. Residual diamine 
crosslinker was removed via dialysis against methylene chloride with Spectra/Por Dialysis 
Tubing (MWCO = 10,000). Nanosponges were made from poly(VL-co-AVL) using Sn(OTf)2 
and Sn(Oct)2 catalysts. 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: Decrease in number of 
epoxide protons at 2.96, 2.75 and 2.47 ppm and the appearance of signals at 3.5 and 2.89 ppm 
corresponding to the protons near the secondary amine of the diamine crosslinker after the 
reaction. 
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Drug Encapsulation of Paclitaxel and Camptothecin in Nanoparticles 
Poly(VL-co-AVL-co-EVL) nanoparticles were encapsulated separately with either paclitaxel or 
camptothecin and emulsified with D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin 
E-TPGS). Nanoparticles (30 mg) and paclitaxel (10 mg) were dissolved together in 1 mL 
dimethyl sulfoxide (DMSO), and nanoparticles (30 mg) and camptothecin (30 mg) were 
dissolved together in 2 mL DMSO prior to dropwise addition to a solution of 0.5% and 2% 
vitamin E-TPGS in distilled water, respectively. The solution was stirred vigorously to form a 
cloudy white suspension over 1-2 minutes and decanted into 50 mL centrifuge tubes. They were 
centrifuged at 7800 rpm for 30 min, and the pellet washed three times by reconstitution in water 
and centrifugation at 7800 rpm for 30 min each. The emulsified drug encapsulated nanoparticles 
were then lyophilized to produce a powder and analyzed by UV-Vis spectrophotometry to give 
approximately 15% drug encapsulation for each drug. (See appendix for calibration curves for 
each drug). 
Cell Culture  
Murine Lewis lung carcinoma (LLC) and A549 lung human carcinoma cells were obtained from 
the American Type Culture Collection (Rockville, MD,). They were grown to 70% confluence in 
Dulbecco’s Modified Eagle Medium or F-12K medium each supplemented with 10% fetal 
bovine serum and 1% antibiotic/antimycotic, respectively. All cultures maintained at 37°C in 
incubator with 95% humidity and 5% CO2. 
Flow Cytometry 
Serum-starved cell cycle analysis  
LLC cells were phase synchronized with serum deprived cell media for 24 hrs prior to treatment 
at IC50 concentrations for each drug or nanoparticle controls for 24 hrs. Sequential treatment 
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groups were also treated with drug loaded nanoparticles for 24 hrs (12 hrs each drug, washed 
with PBS before second drug), washed with PBS, detached and fixed with cold 70% ethanol. All 
cells were stained with a solution of propidium iodide (50 µg/mL) in PBS with 0.1% Triton X-
100 and RNase (200 µg/mL) overnight at 4 °C. After washing twice with PBS, cells were filtered 
and analyzed by flow cytometry.  
Apoptosis studies  
LLC cells were seeded in 6-well tissue culture plates and incubated for 24 hrs. After 72 hrs 
treatment with drug encapsulated nanoparticles or untreated controls, cells were washed with 
PBS, detached and fixed with cold 70% ethanol. Cells were then incubated with rabbit anti-
cleaved caspase-3 primary antibody, washed and incubated with FITC labeled secondary 
antibody. After washing twice with PBS, cells were filtered and apoptotic cell populations were 
quantified by flow cytometry.  All flow cytometry performed using a Becton Dickinson 3-laser 
LSRII flow cytometer. Results were analyzed using FlowJo software. 
Microtubule and proliferation studies: Cell imaging 
Human A549 lung carcinoma cells were grown on cover slips and treated with drug loaded 
nanoparticles or vehicle (DMSO) for 72 hrs, at IC50 (10 µM for NP PTX and 1 µM for NP CPT) 
concentrations for each drug or nanoparticle controls. Simultaneous treatment groups were 
treated with drug-loaded nanoparticles for 72 hrs (NP PTX/NP CPT) Sequential treatment groups 
were treated with drug-loaded nanoparticles for 72 hrs. NP PTX à NP CPT group was exposed 
to PTX for 36 hrs, washed with PBS and exposed to CPT for another 36 hrs. NP CPT à NP 
PTX group was exposed to CPT for 36 hrs, washed with PBS and exposed to PTX for another 36 
hrs.  All groups were washed twice with PBS and fixed with 4% paraformaldehyde. 
Microtubules were stained with anti-beta tubulin antibody conjugated with FITC. Proliferating 
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cells were stained with human anti-Ki67 antibody conjugated with Alexa Fluor 647.  Slides were 
mounted using FluoroShield prior to confocal microscopy. In vitro imaging was performed using 
a Zeiss LSM 710 Meta Inverted confocal microscope at 63x magnification. Images were 
acquired from three fields of view and the numbers of cells showing changes in microtubule 
morphology or expression of Ki67 cell proliferating marker were counted. Bar graphs shown 
represent the number of cells as a percentage of total cells counted. All images were analyzed 
using MetaMorph and ZEN image acquisition and analysis software. 
 
Results and discussion 
Drug release studies: Paclitaxel and Camptothecin 
Poly(VL-co-AVL-co-EVL) nanosponges of varying cross-linking density (5% and 8%) 
were loaded separately with paclitaxel or camptothecin for analysis of drug release over time 
(Figure 3.2). Nanosponges with lower cross-linking density (5% epoxide) were observed to have 
a faster drug release rate for paclitaxel, with over 20% of total drug loaded being released by 24 
hrs. In contrast, nanosponges of similar cross-linking density loaded with camptothecin showed 
less than 10% release by 24 hrs. Nanosponges with higher cross-linking density (8% epoxide) 
were observed to have a relatively slower drug release rate for paclitaxel, with approximately 
10% release by 24 hrs. This pattern is also observed with camptothecin, with approximately 10% 
release by 24 hrs as well. Differences in molecular weight and hydrophobicity may affect the rate 
of drug release in these drugs, by affecting the rate at which individual drug molecules diffuse 
out of the nanosponge.  
Cytotoxicity Studies 
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Nanosponges were loaded separately with paclitaxel, camptothecin, or seliciclib and used to treat 
mouse and human lung carcinoma cells. In vitro dose-response curves for mouse lung cancer 
cells LLC (left) and human A549 (right) were treated with various drug combinations for 24 hrs 
(Figure 3.3). In both cell lines, the combination of paclitaxel/camptothecin lowered IC50 values 
most followed by camptothecin/seliciclib and paclitaxel/seliciclib. 
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Figure 3.2. Drug release studies with poly(VL-co-AVL-co-EVL) nanosponges in phosphate 
buffered saline at 37 °C. (A) Paclitaxel loaded nanosponges with 5% and 8% cross-linking 
density and (B) Camptothecin loaded nanosponges with 5% and 8% cross-linking density. 
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Figure 3.3. MTT cytotoxicity assays with poly(VL-co-AVL-co-EVL) nanosponges of 5% 
epoxide cross-linking density. In vitro dose-response curves for lung cancer cells LLC (left) and 
A549 (right) treated with various drug combinations for 24 hrs. In both cell lines, the 
combination of paclitaxel/camptothecin lowered IC50 values most followed by 
camptothecin/seliciclib and paclitaxel/seliciclib. 
 
In this study we synthesized ‘nanosponges’ (see chapter 2) for tumor-specific delivery of 
hydrophobic small molecule chemotherapeutics paclitaxel (NP PTX) and camptothecin (NP 
CPT), and to evaluate in vitro effects on cell cycle, microtubule dynamics, cell death and 
proliferation. In order to study the effects of this drug combination on cell cycle, LLC cells were 
phase synchronized by serum starvation prior to treatment with monotherapy controls and dual 
drug combinations for 24 hrs (Figure 3.4A-C). Flow cytometry analysis of cell cycle showed the 
highest levels of G2/M phase arrest with sequential NP PTX à NP CPT treatment (67%), a 28% 
increase compared to simultaneous treatment, and 34% increase over the reverse sequential  
treatment NP CPT à NP PTX. Sequential NP PTX à NP CPT showed 13% increase compared 
to NP PTX and 26% increase over NP CPT monotherapy controls, and 52% increase over NP 
controls (Figure 3.4A-C). Interestingly, the highest levels of S phase arrest were seen with 
	   70	  
simultaneous treatment, and among the lowest in the sequential NP PTX à NP CPT group, 
indicating the sequence of drug administration drove many more cells into G2/M phase arrest 
than would otherwise have occurred with the drug combination itself (Figure 3.4).  
 
 
 
 
 
Figure 3.4. Flow cytometry histograms (A) representing cell cycle distributions of LLC cells 
treated with dual drug combinations (simultaneous NP PTX/NP CPT and sequential NP CPT→ 
NP PTX and NP PTX→ CPT) or monotherapy controls (NP Control, NP PTX and NP CPT). 
G2/M phase cell cycle arrest in response to monotherapy and dual drug combinations (B). 
Percentage of cells in all measured cell cycles: G0, G1, S and G2 phases after monotherapy and 
dual drug treatment (C).  
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Figure 3.4. Confocal microscopy analysis of microtubule aggregation and cell proliferation in 
A549 lung carcinoma cells treated for 72 hrs at IC50 concentrations for each drug. Cells were 
fixed, stained for cellular beta tubulin (green) and Ki67 (red) in 63x magnification. Scale bar 
indicates 20 µm (D). Percentage of dual drug treated cells vs. monotherapy controls exhibiting 
microtubule aggregation (green) (E), percentage of dual drug treated cells vs. monotherapy 
controls expressing Ki67, a marker for cellular proliferation (red) (F). Bars, mean and SE for 
n=3, unpaired Student’s t test (p<0.05).        
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Since microtubules and their associated proteins play a role in the cell cycle and help 
regulate mitosis, microtubule disrupting drugs such as paclitaxel can have multiple 
effects on cells.24,25 Therefore, the effect of paclitaxel and camptothecin drug 
combinations on microtubule morphology in lung cancer cells was examined. Figure 3.4 
shows confocal images of marked microtubule aggregation seen in all paclitaxel 
treatment groups compared to NP only controls. The greatest percentage of cells with 
morphological changes in microtubule structure can be seen with sequential NP PTX à 
NP CPT treatment, with 95.8% of cells exhibiting microtubule-induced ‘bundles’ 
compared to normal microtubule networks seen in NP controls (Figure 3.4). The reverse 
sequence showed only 54.5% of cells affected, and simultaneous treatment produced 
69.4% of cells with microtubule changes (Figure 3.4). In comparison, NP PTX showed 
the greatest microtubule changes among the monotherapy controls with 67.9% of cells 
affected and NP CPT showed only 23.7% cells with affected microtubules (Figure 3.4E). 
Interestingly, the simultaneous dual drug combinations (NP PTX / NP CPT) primarily 
showed evidence of microtubule ‘bundles’, where NP PTX monotherapy controls showed 
microtubule ‘asters’ radiating from centrosomes (Figure 3.4D, insets). These 
morphological changes are consistent with cell cycle changes as mitotic asters generally 
appear in cells undergoing mitosis whereas bundling occurs more throughout G2 phase.24-
27 These results may indicate that addition of camptothecin contributes to cell cycle arrest 
and prevents entry into mitosis. Additionally, reorganization of microtubules into bundles 
may correlate with sensitivity of cells to camptothecin, with initial exposure to paclitaxel 
enhancing the sensitivity of lung cancer cells to the effects of camptothecin. Changes in 
cell proliferation can also be seen with the least number of cells proliferating (54.2%) 
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with sequential NP PTX à NP CPT treatment, compared to the reverse sequence at 
72.7% and simultaneous treatment showing 62.9% proliferation. Monotherapy controls 
had the highest levels of proliferation with NP PTX showing 86.8% of cells still 
proliferating, NP CPT showing 71.1%, and NP controls with the highest population of 
cells proliferating at 89.2% (Figure 3.4F). In addition, sequential treatment with 
paclitaxel and camptothecin was also performed on PC-3 prostate cancer cells in order to 
observe changes in microtubule morphology (Figure 3.5). Results from these studies 
validate those observed in lung cancer cell lines, indicating that cells receiving the 
sequential treatment NP PTX à NP CPT showed the greatest level of microtubule 
polymerization compared to both monotherapy and reverse sequence controls.  
 
 
 
 
 
 
 
 
Figure 3.5. Sequential treatment with NP-paclitaxel before NP-camptothecin exhibited 
greater tubulin polymerization compared to the reverse sequence, NP-paclitaxel alone 
and untreated controls. PC-3 cells treated 24 hrs with NP camptothecin 12 hrs followed 
by NP-paclitaxel, and the reverse sequence of NP-paclitaxel then NP-camptothecin. Cells 
stained for tubulin polymerization (green) and nuclei counterstained with DAPI (blue). 
Fluorescence microscopy images obtained at 20x magnification.  
 
 
!
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In order to evaluate effects on cell death, LLC cells treated as described above were fixed 
and stained for caspase-3 expression, prior to analysis by flow cytometry. Figure 3.6 
shows that cells receiving the sequential treatment NP PTX à NP CPT expressed the 
highest levels of caspase-3 protein, followed by the reverse sequence and NP PTX only, 
simultaneous NP PTX/NP CPT, NP CPT and NP controls. 
 
 
Figure 3.6. Flow cytometry analysis of caspase-dependent cell death in Lewis lung 
carcinoma cells treated for 72 hrs at IC50 concentrations for each drug. Cells were stained 
for presence of caspase-3 and analyzed by flow cytometry. Bars, mean and SE for n=3, 
unpaired Student’s t test (p<0.05). 
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Conclusion 
This study investigated the feasibility of using nanosponge encapsulated 
paclitaxel and camptothecin to determine the optimum drug combination and sequence 
for treating lung cancer. Here, the role of drug combination and sequence in vitro, in both 
mouse and human lung cancer cell lines, was investigated using synthesized nanosponges 
loaded with either paclitaxel (NP PTX) or camptothecin (NP CPT). Results showed not 
only that paclitaxel and camptothecin combination therapy produced the greatest G2/M 
phase arrest compared to monotherapy, but also that sequential administration of NP PTX 
followed by NP CPT further enhanced caspase-dependent cell death compared to 
simultaneous administration. Paclitaxel, more so than campthothecin, was observed to 
drive cells into G2/M phase arrest and subsequent apoptosis. Further studies are 
necessary to determine the molecular basis for this effect in lung cancer. Sequential 
administration (NP PTX → NP CPT) of nanoparticle drug delivery systems resulted in 
greater cell death and decreased cell proliferation. Collectively, these studies suggest that 
dual combination treatment with administration of paclitaxel prior to camptothecin 
produces greater G2/M phase arrest, microtubule aggregation, cell death and reduced 
proliferation compared to simultaneous and monotherapy treatment. In addition, 
paclitaxel appears to show a ‘priming’ effect on the cells that enhances camptothecin’s 
effect on cells when given second.  
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CHAPTER 4 
 
SYNTHESIS AND BIOLOGICAL EVALUATION OF CYCLIC RGDEKf-Ahx-C 
FUNCTIONALIZED NANOSPONGES FOR IN VITRO 
TUMOR TARGETING AND IMAGING IN A LUNG CANCER MODEL 
 
Abstract  
Integrins are an important target for many chemotherapeutic treatments, and RGD 
targeted nanoparticles have the potential to deliver various imaging and therapeutic 
agents to the α!β3 integrin expressing tumor vasculature. Development of RGD probes 
for tumor imaging has created the need for greater affinity and stability of these ligands 
in vivo. Cyclic RGD peptides exhibit enhanced stability and decreased susceptibility to 
chemical and enzymatic degradation compared to their linear counterparts. In this study 
we synthesized a cyclic RGD peptide of the sequence RGDEKf-Ahx-C as a targeting 
ligand for tumor-specific targeting of nanoparticles to lung cancer cells in vitro. This 
cyclic RGD tumor targeting peptide was synthesized using solid phase peptide synthesis, 
attached to nanoparticles, and modified with a fluorescent probe for in vitro cell imaging 
applications. Confocal microscopy showed competitive binding of cyclic RGD targeted 
nanoparticles compared to untargeted controls and competitive binding vitronectin 
controls. These results indicate that this cyclic RGD peptide binds specifically in a dose 
responsive way to the α!β3 integrin receptor present on lung cancer cells in vitro, and can 
be used to target nanoparticles specifically to this receptor on cancer cells.  
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Introduction 
Integrins as therapeutic targets 
Integrins are heterodimeric glycoproteins that mediate cellular adhesion to other 
cells and extracellular matrix.1 They also function as receptors by binding to ligands with 
exposed arginine-glycine-aspartate (RGD) sequences.2 These receptors interact with 
extracellular ligands and stimulate intracellular signaling and gene expression in various 
cellular processes. They also play a role in invasion and metastasis of cancer cells, tumor 
growth and angiogenesis.1-6 As a result, integrins have become an attractive target for 
many chemotherapeutic treatments, and the development of RGD peptide ligands that 
could bind to these integrin receptors has been a rich source of potential tumor targeting 
agents.  
 
RGD peptide ligands  
The Arg-Gly-Asp (RGD) amino acid sequence was  found to be a binding ligand 
to the α!β3 integrin in the early 1970s by Ruoslahti and colleagues.8-12 It was originally 
identified as a cell binding site in the extracellular matrix protein fibronectin, but later on 
this sequence was recognized as the amino acid motif present in many natural ligands 
binding the α!β3 receptor, including fibrinogen, fibronectin, and vitronectin.8-12 Proteins 
that contain an RGD binding motif, along with their integrin receptors, are a major 
recognition system for cell adhesion processes. The integrin-binding activity of adhesion 
proteins can be reproduced by short synthetic peptides containing the RGD sequence. 
The diverse applications for these peptides include inhibiting angiogenesis and tumor 
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formation, coating surfaces for use as biomaterials, enhancing drug delivery systems, and 
imaging for diagnostic purposes.3-5  
 
Linear vs. Cyclic RGD peptides 
Development of RGD probes for tumor imaging has created the need for greater 
affinity and stability of these ligands in vivo.22-25 As a result, differences in conformation 
and structure have been studied between many linear and cyclized forms of different 
RGD containing peptides to determine the most stable conformation. Optimization of 
peptide length and spatial orientation has led to the development of cyclic RGD peptides 
that more closely mimic naturally occurring proteins that bind the α!β3 integrin receptor.8 
It has been demonstrated that cyclization of these RGD peptides enhances stability and 
decreases susceptibility to chemical and enzymatic degradation, partly because of the 
increased conformational stability of the cyclic peptide compared to the linear 
peptide.14,19 One of these cyclic peptides, cyclo(RGDf(NMe)V) (Cilengitide) has been 
used to treat glioblastoma in clinical trials.18-24 Another way to improve affinity is to 
increase the number of molecules available for binding (multivalency) via 
nanoparticles.13,20,21 This binding strategy exploits the surface of nanoparticles as a 
platform for peptide ligand attachment, and is an effective way for obtaining high affinity 
molecular binding.20,21 
 
Synthesis and optimization of RGD peptides 
Optimization of solid-phase peptide synthesis requires the use of coupling 
reagents best suited to the formation of peptide bonds. Typical peptide synthesis methods 
	   83	  
use a benzotriazole (such as HOBt and its derivatives) in combination with 
carbodiimides, or immonium (HBTU) and phosphonium (PyBOP) salts.15,16 More 
recently, a uronium salt (COMU) has been shown to have greater coupling efficiency and 
lower racemization than its predecessors, making it a superior reagent for the formation 
of an amide bond.15,16 In addition, shorter coupling reaction times and higher purity 
peptides make COMU a suitable choice for synthesis of cyclic peptides.15,16  
 
Integrin targeted tumor imaging 
To reach tumor cells and tumor-associated parenchymal cells, drugs must cross 
the vascular barrier and penetrate into the stroma. Cancer tissue is heterogeneous, with 
vast differences in tumor structure and physiology. These features translate into steep 
drug gradients and variability in the uptake and distribution of anti-cancer drugs.7 
Although cancer cells are inherently more vulnerable to chemotherapy than the majority 
of normal cells, most chemotherapy drugs are not very selective and can harm normal 
tissues as well. Because of the particular characteristics of the tumor microenvironment 
and tumor angiogenesis, it is possible to design drug delivery systems that specifically 
bring chemotherapy drugs to tumors. Nanometer-sized drug delivery systems can target 
tumors by a passive or active process. Active targeting involves drug delivery to a 
specific site based on molecular recognition, providing the greatest efficiency for cancer 
chemotherapy.5 One approach is to conjugate a ligand that can interact with a receptor at 
the target cell site to a nanoparticle. The angiogenic phenotype of the tumor vasculature, 
and some proteins or receptors expressed at the surface of the endothelial cells are 
considered attractive targets for delivering nanoparticles to tumors. The most popular 
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example is the integrin adhesion molecule α!β3. The α! integrin subunit is highly 
expressed on endothelial cells lining tumors, whereas it is poorly expressed in healthy 
endothelial cells. Targeting the α!β3 integrin with drugs may thus provide an opportunity 
to destroy tumor vessels but keep vessels from normal tissues intact. However, the use of 
complicated modification techniques and the poor conjugation efficiency of the targeting 
ligands have limited the application of most of the nano-sized drug delivery systems.8 
 Peptides based on mentioned the RGD sequence have been used extensively as 
tumor targeting ligands in diagnostics and therapeutics, as they bind preferentially to α!β3 
integrins. RGD-targeted nanocarriers have the potential to deliver various therapeutic 
agents to the α!β3-expressing tumor vasculature. Since the integrins are specifically over-
expressed at the surface of tumor cells and angiogenic endothelial cells at the tumor site, 
RGD-mediated drug delivery generally leads to high levels of accumulation in tumor 
tissues compared to unmodified drug or non-targeted drug delivery systems. Both linear 
RGD and cyclic RGD have been applied for targeted delivery of drugs, genes and 
polymers. Furthermore, there are studies showing that cyclic RGD peptides are more 
stable than their linear precursors.14,19 The increase in stability of the cyclic peptide 
compared with the linear peptide is due to decreased structural flexibility imposed by the 
ring.12 In this study we synthesized a cyclic RGD peptide of the sequence RGDEKf-Ahx-
C as a targeting ligand for tumor-specific targeting of nanosparticles to lung cancer cells 
in vitro. 
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Experimental 
Materials and Methods 
Materials 
Chemical reagents were purchased from Sigma-Aldrich and Strem Chemicals, 
chemotherapeutic drugs from LC Laboratories. Spectra/Por Dialysis membrane 
(MWCO=10,000) in 0.05% sodium azide was purchased from Spectrum Laboratories.  
Preparation of Monomers 
δ-valerolactone monomer (VL) 
Technical grade δ-valerolactone was Kugelrohr distilled to produce a colorless liquid 
product.  
α-allyl-δ-valerolactone monomer (AVL) 
A flame dried 500 mL two-necked round bottom flask was equipped with a stir bar, 
sealed with a rubber septum, and purged with nitrogen for 30 min. To the flask, 156.25 
mL of anhydrous THF was added and cooled to -78 °C in a dry ice/acetone bath. 
Following this, a basic solution of lithium diisopropylamine was produced by adding 
redistilled n,n-diisopropylamine (3.3 mL, 23.63 mmol) and n-butyl lithium (2.5 M in 
hexanes) (9.35 mL, 23.38 mmol) dropwise via syringe. This solution was stirred for 20 
minutes. A nitrogen purged solution of distilled δ-valerolactone (1.97 mL, 21.23 mmol) 
in anhydrous THF (56 mL) was then added dropwise via syringe over 30 min. After an 
additional 30 min of stirring, a nitrogen purged solution of allyl bromide (2.21 mL, 25.54 
mmol) in hexamethylphosphoramide (4.43 mL, 25.46 mmol) was added via syringe. The 
reaction mixture was warmed up to -40 ºC and stirred for 2 hrs. The reaction was 
quenched with excess NH4Cl solution. The crude product was concentrated via rotary 
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evaporator, washed three times with saturated NaCl solution, and dried with anhydrous 
magnesium sulfate. The crude product was purified via column chromatography (Biotage 
Isolera), analyzed by thin layer chromatography and Kugelrohr distilled. 
Chromatography with a gradient of 5-20% ethyl acetate in n-hexanes as eluent gave a 
yellow liquid product. Kugelrohr distillation produced a colorless liquid product. Yield: 
3.56 g (89%). 1H NMR (400 MHz, CDCl3/TMS, ppm) δ: 5.7 (m, 1H, H2C=CH-), 5.08 
(m, 2H, H2C=CH-), 4.28 (m, 2H, -C(O)OCH2-), 2.53-2.58 (m, 2H, H2C=CHCH2-), 2.27 
(m, 1H, H2C=CHCH2CH-), 2.06 (m, 1H, H2C=CHCH2CHCH2-), 1.89 (m, 2H, 
C(O)OCH2CH2-), 1.55 (m, 1H, H2C=CHCH2CHCH2-). 
Preparation of Linear Polymer Precursors 
Poly(VL-co-AVL) 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed 
with rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in 
anhydrous tetrahydrofuran was prepared (1.7 M) in a 50 mL flame dried round and 
nitrogen purged round bottom flask, and a stock solution of Sn(OTf)2 catalyst in 
anhydrous tetrahydrofuran was prepared (3.7x10-2 M) in a 10 mL flame dried and 
nitrogen purged round bottom flask.  Ethanol (584 µL, 1.0 mmol) and Sn(OTf)2 (261 µL, 
9.64 x 10-6 mol) were added via syringe to the 25 mL 3-neck round bottom flask and the 
catalyst/initiator solution was allowed to stir at room temperature for 30 minutes prior to 
simultaneous addition of δ-valerolactone (2.22 g, 22.0 mmol) and α-allyl(valerolactone) 
(0.777 g, 5.548 mmol) monomers via syringe.  After addition of both monomers, the 
reaction was stirred for 24h at room temperature. The resulting polymer was diluted with 
1 mL anhydrous THF and purified by dropwise addition into 1 L of chilled methanol to 
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remove any remaining monomer and catalyst. The methanol was decanted and the 
precipitate redissolved in methylene chloride, rotary evaporated and dried in vacuo. The 
resulting polymer was observed as a waxy white solid.  Mw = 3000 Da; PDI = 1.09; 1H 
NMR (400 MHz, CDCl3/TMS, ppm) δ: 5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 
(m, -CH2-O-), 3.64 (m, CH3CH2O-), 2.34 (m, vl, -CH2CH2C(O)O-, avl, H2C=CHCH2CH, 
H2C=CHCH2CH-), 1.68 (m, avl and vl, -CHCH2CH2-), 1.26 (t, CH3CH2O-). 
Poly(VL-co-AVL-co-EVL) 
In a 100 mL round bottom flask, equipped with stir bar and rubber septum, a solution of 
poly(VL-co-AVL) (1.0 g, 1.55 x 10-3 mol) was dissolved in 8.5 mL of methylene 
chloride. To this solution, meta-chloroperoxybenzoic acid (121.25 mg, 7.03 x 10-4 mol) 
was added. The solution was stirred for 24 hrs at room temperature and then concentrated 
via rotary evaporator. The crude product was dissolved in a minimal amount of 
dichloromethane (2 mL) and precipitated into an Erlenmeyer flask containing 500 mL 
cold diethyl ether. The solution was decanted, and the white solid was rotary evaporated 
and dried in vacuo to obtain the final white waxy polymer. Yield: 0.768 g (76.8%). 1H 
NMR (400 MHz, CDCl3/TMS, ppm) δ: Decrease in allylic protons at 5.7 and 5.09 ppm 
and the appearance of small broad resonance peaks at 2.96, 2.75 and 2.47 ppm due to the 
formation of the epoxide.  
Formation of nanoparticles 
In a 250 mL round bottom flask equipped with stir bar and reflux condenser, a solution of 
2,2'-(ethylenedioxy)diethylamine (10.5 µL, 7.18x10-5 mol) in 29.55 mL methylene 
chloride was heated at 45 °C. A solution of poly(VL-co-AVL-co-EVL), (0.200 g, Mw= 
3000 Da) dissolved in methylene chloride was added. The mixture was refluxed at 45 ºC 
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for 12 h. Residual diamine crosslinker was removed via dialysis against methylene 
chloride with Spectra/Por Dialysis Tubing (MWCO =10,000). 1H NMR (400 MHz, 
CDCl3/TMS, ppm) δ: Decrease in number of epoxide protons at 2.96, 2.75 and 2.47 ppm 
and the appearance of signals at 3.5 and 2.89 ppm corresponding to the protons near the 
secondary amine of the diamine crosslinker after the reaction.  
Peptide Targeted Nanoparticles  
Addition of targeting peptide via photoinitiated thiol-ene ‘click’ reaction 
Poly(VL-co-AVL-co-EVL) nanosponges were dissolved in dichloromethane and purified 
using Sephedex column chromatography, rotary evaporated and dried in vacuo. 
Anhydrous, degassed DMSO (1 mL) was used to dissolve 20 mg of poly(VL-co-AVL-
co-EVL) nanosponges, 10 mg of cRGD peptide and 1 mg DMPA. Mixture was stirred for 
2 days in an oil bath at 37 °C under ultraviolet light at 365 nm. The product was purified 
by dialysis (MWCO 10,000) against methanol/acetonitrile (1:1) for 2 days, rotary 
evaporated and dried in vacuo.  
Quantification of peptide units on nanoparticles via 1H NMR: 
Since the primary thiol functional group from the cysteine residue in the peptide 
(RGDEKf-Ahx-C) reacts with the allyl groups in the nanoparticle in a 1:1 stoichiometry, 
the allyl groups that are consumed in the reaction directly correlate with how many 
peptides are bound to the nanoparticle. By comparing the percent allyl groups in the 
nanoparticle before and after peptide attachment, the difference can be used to calculate 
the number of bound peptides. The nanoparticle peak at 4.08 ppm is used as an internal 
standard for determining the number of unmodified allyl groups remaining after the 
photoinitiated thiol-ene click reaction for peptide attachment. 
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Modification of RGDEKf-Ahx-C-NPs for confocal imaging with NHS Alexa Fluor 488  
RGDEKf-Ahx-C modified poly(VL-co-AVL-co-EVL) nanosponges and unmodified 
nanoparticles were separately dissolved in anhydrous DMSO. To each solution, NHS 
Alexa Fluor 488 was added and the resulting mixture was stirred for 6 hrs (covered in foil 
to protect from light). The product was purified by dialysis (MWCO =10,000) against 
methanol/acetonitrile (1:1) overnight, rotary evaporated and dried in vacuo (covered in 
foil to protect from light).  
Solid Phase Peptide Synthesis of RGDEKf-Ahx-C peptide 
All Amino acids used were protected by 9-fluoromethoxycarbonyl (Fmoc) and were 
purchased from Advanced ChemTech (Louisville, KY). They included Fmoc-L-
Glu(ODmab)-OH, Fmoc-L-Asp(OtBu)-OH, Fmoc-L-Gly-OH, Fmoc-L-Arg(Pbf)-OH, 
Fmoc-L-Lys(Boc)-OH, Fmoc-D-Phe-OH, and Fmoc-epsilon-Ahx-OH spacer. An Fmoc-
Cys(Trt)-2-Cl-Trt resin was purchased from AAPPTec (Louisville, KY). (1-Cyano-2-
ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium 
hexafluorophosphate (COMU), N,N-Diisopropylethylamine (DIPEA), trifluoroacetic acid 
(TFA), N,N-dimethylformamide (DMF), dichloromethane (DCM) and piperidine were 
purchased from Sigma Aldrich (St. Louis, MO). HPLC grade acetonitrile (ACN) and 
methanol (MeOH) were obtained from Sigma Aldrich (St. Louis, MO). All chemicals 
were of reagent grade and used as received. HPLC purification of crude peptide was 
performed on a reverse phase column which was eluted with CH3CN in 0.1% aqueous 
TFA and detected at OD 220 nm. 
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Synthesis of cyclic peptides 
Cyclic RGDEKf-Ahx-C was synthesized on the resin via solid-phase peptide synthesis 
methodology using Fmoc strategy, and cyclized in the solvent. The synthesis route could 
be seen in Scheme S1. Briefly, a swelling resin, and further elongation led to a linear 
protected peptide. In each elongation step, coupling was performed with a 2-fold excess 
of Fmoc-amino acid in the presence of COMU/DIPEA mixed solution for 30 min, and 
Fmoc groups were cleaved with 20% (v/v) piperidine in DMF for 10 min. After cleavage 
from resin by 5% TFA/DCM for 2 h, the linear protected peptides were cyclized in the 
solvent by COMU/DIPEA for 2 h. The crude product was yielded after all the protecting 
groups were removed by using 95% TFA/H2O for 2 hrs. The crude cyclic peptides were 
further purified by preparative reversed-phase high performance liquid chromatography 
(RP-HPLC).  
NMR Analysis 
The 1H NMR spectra were obtained on a 600 MHz (Bruker) spectrometer with DMSO-d6 
and TMS as an internal standard. 
Cell Culture 
Human lung carcinoma (A549) cells were purchased from American Type Culture 
Collection (ATCC; Manassas, VA). Cells were cultured at 37 °C in a 5% CO2 atmosphere 
in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) supplemented with 10% fetal 
bovine serum (FBS, Gibco), penicillin antibiotic and streptomycin antimycotic. All 
cultures maintained at 37°C in incubator with 95% humidity and 5% CO2. 
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Cell Imaging  
Human A549 lung carcinoma cells were grown on cover slips and treated with 
synthesized cRGD-NP, untargeted NP controls, or blocked with 1 mg/ml Vitronectin for 
1 hr. All groups were washed twice with PBS and fixed with 4% paraformaldehyde. Cells 
were fixed and visualized by confocal microscopy. In vitro imaging was performed using 
a Zeiss LSM 710 Meta Inverted confocal microscope at 63x magnification. Images were 
acquired from three fields of view. Bar graph shows percent fluorescent intensity. All 
images were analyzed using MetaMorph and ZEN image acquisition and analysis 
software. 
 
Results and discussion 
 
Cyclic RGD peptide was prepared by solid-phase peptide synthesis methods 
(Scheme 4.1). In order to synthesize linear and cyclic RGDEKf-Ahx-C peptides, 
Merrifield solid-phase peptide synthesis (SPPS) methods were used along with Fmoc/tBu 
chemistry.17 An N-protected C-terminal cysteine was anchored via its carboxyl group to a 
polystyrene resin (Scheme 4.1). The peptide sequence was then built linearly from the C-
terminus to the N-terminus using repeated cycles of deprotection and amino acid 
coupling reactions.17 The linear peptide was then cleaved from the resin and any 
remaining protecting groups removed.17 The cyclic peptide was cyclized on the resin 
prior to cleavage and removal of remaining protecting groups. The base–labile N-Fmoc 
group was used to protect the amino functional groups on each amino acid as well as 
acid–labile side-chain protecting groups.17 An ODmab protecting group was used to 
protect the glutamic acid carboxyl group, prior to being removed with 2% hydrazine in 
DMF (Scheme 4.1). The ODmab protection of the carboxyl groups is compatible with the 
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Fmoc strategy as it is stable in piperidine used for peptide synthesis.18 Removal of the 
ODmab group left a deprotected carboxylic acid group available for the final cyclization 
reaction.  
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Scheme 4.1.  Solid-phase peptide synthesis and structure of cyclic RGDEKf-Ahx-C. 
 
Nanosponges of 50-100 nm size were prepared from poly(VL-co-AVL-co-EVL) 
polymers, and functionalized with cyclic RGDEKf-Ahx-C peptide using thiol-ene ‘click’ 
chemistry. The primary thiol functional group from the cysteine residue was reacted with 
allyl functional groups from the nanosponge in a photoinitiated thiol-ene ‘click’ reaction 
(Figure 4.1). The photoinitiator 2,2-dimethoxy-2-phenylacetophenone (DMPA) was used 
in catalytic amounts to initiate a radical reaction in the presence of ultraviolet light (365 
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nm).33,34 Upon absorption of light, DMPA undergoes a homolytic bond cleavage to 
produce two new radicals.33,34 These radical species initiate the thiol-ene reaction by 
attacking the R-SH bond and generating a new sulfenyl radical that propagates the 
reaction by adding to an alkene to form a new carbon radical.33,34 Since this typically 
occurs on the least substituted carbon of the alkene (due to greater stability of the radical 
intermediate formed), the reaction is said to exhibit anti-Markovnikov regioselectivity. 
This new carbon radical further propagates the reaction by reacting with another thiol to 
generate another sulfenyl radical, repeating the cycle.33,34 The reaction terminates when 
two of these sulfenyl or carbon radicals meet and react to form a new bond.33,34  
DMPA photoinitiator 
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+ SHR SR
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Figure 4.1.  Thiol-ene ‘click’ reaction using DMPA photoinitiator. (A) DMPA absorbs 
light and undergoes homolytic bond cleavage producing new radicals. (B) Initiation of 
thiol-ene ‘click’ reaction and generation of sulfenyl radical (C) Propagation of reaction 
with sulfenyl and carbon radicals. (D) Termination of reaction when two radicals meet 
and form a new bond. 
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RGD peptides have been shown to bind to integrins present on cancer cells. Nanosponges 
of 50-100 nm size were modified with these peptides using DMPA photoinitiated thiol-
ene ‘click’ reactions to produce peptide functionalized nanosponges (Figure 4.1).  These 
modified nanosponges were then analyzed by 1H NMR to confirm peptide conjugation 
(Figure 4.2), prior to further functionalization with fluorescent imaging units including 
Alexa fluor 488 for in vitro studies. 
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Figure 4.2.  Photoinitiated thiol-ene ‘click’ attachment of cyclic RGD to nanosponges. 
(A) Cyclic RGDEKf-Ahx-C peptide, (B) Reaction scheme, 1H NMR (600 MHz) spectra 
(C) cyclic RGD-NP (blue), (D) cyclic RGD (green), (E) NP in dmso-d6 (red). 
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Nanosponges functionalized with cyclic RGDEKf-Ahx-C peptide and fluorescent 
imaging moieties were then tested in A549 human lung cancer models to validate α!β3 
integrin receptor targeting (Figure 4.3). Cells were cultured overnight and treated with 
targeted nanosponges, targeted nanosponges and competitor (vitronectin), or untargeted 
control nanosponges.  Following incubation for 1 hr, they were washed twice with 
phosphate buffered saline and prepared for confocal microscopy.  
 
 
 
Figure 4.3.  Imaging RGDEKf-Ahx-C-NP-AF488 binding to cells (cell imaging, bar 
graph of fluorescence). (A) Confocal microscopy analysis of integrin specific targeting in 
A549 lung carcinoma cells treated with synthesized cRGD-NP, untargeted NP controls, 
or blocked with 1 mg/ml Vitronectin for 1 hr. Cells were fixed and visualized by confocal 
microscopy.  Zeiss LSM 710, 63x magnification. (B) Bar graph of fluorescence intensity. 
Bars, mean and SE for 3 fields of view. Unpaired Student’s t test (P ≤ 0.05) 
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The α!β3 integrin receptor present on cancer cell membranes is known to bind RGD 
ligands and peptides with RGD motifs. In order to determine preferential RGD peptide 
binding to integrin receptors, vitronectin (a glycoprotein with an RGD sequence) was 
used to compete with the specific binding of peptides to integrins. Cells treated with the 
targeted group alone show significantly greater fluorescence along the membrane and 
peripheral areas compared to cells treated with vitronectin competitor and untargeted 
controls (Figure 4.4). These studies validate cyclic RGD peptide targeting to integrin 
receptors in human lung cancer cells and show preferential binding compared to 
untargeted controls.  
 
 
Figure 4.4.  Imaging vitronectin competition studies with RGDEKf-Ahx-C-NP-AF488.  
(cell imaging, bar graph of fluorescence). Competition assay with 0, 0.5 and 1 mg/ml 
Vitronectin for 1 hr.  
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Conclusion 
These studies show the synthesis of a cyclic RGDEKf-Ahx-C tumor targeting 
peptide, attachment to nanosponges, and modification with a fluorescent probe for in 
vitro cell imaging applications. Confocal microscopy shows competitive binding of 
cyclic RGD targeted NPs compared to untargeted controls and competitive binding 
controls with vitronectin competitor. These results indicate that this cyclic RGD peptide 
binds specifically in a dose responsive way to the α!β3 integrin receptor present on lung 
cancer cells in vitro, and can be used to target nanosponges specifically to this receptor 
on cancer cells.  
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CHAPTER 5 
 
SEQUENTIAL TARGETED DELIVERY OF PACLITAXEL AND 
CAMPTOTHECIN USING A CROSS-LINKED ‘NANOSPONGE’ NETWORK 
FOR LUNG CANCER CHEMOTHERAPY 
 
Abstract 
The applicability of a HVGGSSV peptide targeted ‘nanosponge’ drug delivery 
system for sequential administration of a microtubule inhibitor (paclitaxel) and 
topoisomerase I inhibitor (camptothecin) was investigated in a lung cancer model. In vivo 
molecular imaging and TEM studies validated HVGGSSV-NP tumor binding at 24 hrs 
and confirmed the presence of Nanogold labeled HVGGSSV-NPs in tumor microvascular 
endothelial cells. Therapeutic efficacy studies conducted with sequential HVGGSSV 
targeted NP PTX and NP CPT showed 2-fold greater tumor growth delay in combination 
versus monotherapy treated groups, and 4-fold greater delay compared to untargeted and 
systemic drug controls. Analytical HPLC/MS methods were used to quantify drug 
content in tumor tissues at various time points, with significant paclitaxel and 
camptothecin levels in tumors 2 days post-injection and continued presence of both drugs 
up to 23 days post-injection. The efficacy of the NP drug delivery system in sequential 
treatments was demonstrated in in vivo lung cancer models resulting in enhanced 
apoptotic cell death, decreased cell proliferation and vascular density. 
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Introduction 
Many conventional chemotherapy protocols for the treatment of cancer produce 
side effects that limit biological efficacy and compromise patient outcomes.1 In addition 
to affecting proliferating cancer cells, these cytotoxic drugs also affect other rapidly 
dividing cells including cells in the gastrointestinal tract, bone marrow cells and hair 
follicles. Additionally, due to the hydrophobic nature of many chemotherapeutic drugs, 
parenteral administration via intravenous infusion typically requires the use of 
formulation vehicles (such as Cremophor® EL), which have been noted to produce 
undesirable biological reactions such as hypersensitivity and toxicity. Although the 
development of targeted drug delivery systems has allowed cytotoxic chemotherapeutics 
to be administered selectively to malignant tumors while sparing healthy tissues from 
undesirable side effects, solubilization of drugs and tailoring the drug dosage remain a 
challenge.2,3 Therefore, degradable drug carriers are being developed to target and release 
drugs in a controlled fashion.4-6 In particular, ‘nanosponge’ materials have been found 
suitable due to their degradable polyester based nano-network, comprised of a cross-
linked 3-dimensional scaffold, which can be synthesized in different sizes, network 
densities and can be functionalized with tumor targeting units and imaging agents to 
enable visualization in vivo.7-9  Moreover, hydrophobic drugs can be loaded into these 
nanosponges via a developed nanosolublization method to result in readily injectable 
formulations for direct administration to create a linear release of the drug.8  
Previous studies have shown that functionalization of nanosponges with tumor 
targeting peptides enhances targeting and significantly reduces tumor growth in a breast 
cancer model compared to systemic paclitaxel.10 Targeting of a wide variety of tumors 
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(breast, brain, lung, prostate, colon, etc.) with peptides to radiation-inducible receptors 
expressed following exposure to sub-therapeutic levels of ionizing radiation has been 
previously established.2,10-13 These results motivated us to investigate combination 
chemotherapy with paclitaxel and camptothecin in order to capitalize on the 
advantageous features of the nanosponge drug delivery system for tumor-specific drug 
targeting, release and solubilization. In this study, the Tax-interacting protein 1 (TIP-1) 
targeting peptide (HVGGSSV) was used to guide the delivery system to lung tumors 
treated with ionizing radiation in a murine lung cancer model.14   
In addition to tumor targeting, the potential of sequential combination drug 
delivery using these targeted nanocarriers is investigated using mitotic inhibitors and 
topoisomerase I inhibitors, in addition to establishing tumor targeting of these 
nanosponges. Paclitaxel (Taxol) has shown promise as a chemotherapeutic alone and in 
combination with other drugs such as camptothecin in the treatment of a variety of 
cancers.15,16 As a mitotic inhibitor, its main mechanism of action involves the 
stabilization of microtubules, G2/M phase cell cycle arrest, disruption of mitosis, and 
apoptosis.15 Camptothecin is a topoisomerase I inhibitor that causes DNA damage by 
reversibly stabilizing the covalent enzyme-DNA intermediate, causing DNA double 
strand breaks, S/G2 cell cycle arrest and apoptosis.17-19 Despite its potency, the use of 
camptothecin in the clinic has been limited greatly due to its poor water solubility, 
toxicity and side effects. While analogues of camptothecin, such as Irinotecan and 
Topotecan, have been developed to enhance water solubility, toxicity still remains a 
limiting side effect.20 As a result, targeted drug delivery systems that can provide 
sustained release of highly hydrophobic small molecules specifically at tumor sites 
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exhibit particular promise for combination chemotherapy where delivery of lower doses 
for extended times can help enhance efficacy and reduce toxicity. Moreover, continuous 
low doses of drug over time (metronomic chemotherapy), also allow for greater anti-
angiogenic efficacy.21 Biodegradable targeted nanosponges with a cross-linked polymeric 
architecture create controlled low dose drug release profiles that are highly suitable for 
this application. Furthermore, development of a tumor-specific drug delivery system that 
enhances drug solubility, provides sustained low dose drug release, and can be used with 
different drug combinations provides a unique opportunity for maximizing the potential 
of chemotherapy while reducing the limiting toxicities that lower treatment efficacy.22, 23 
This work describes a comprehensive study using a developed targeted 
‘nanosponge’ nanoparticle as carriers in a sequential combination treatment approach for 
lung cancer, which has not been investigated despite the known potency of both 
paclitaxel and camptothecin. Briefly, HVGGSSV targeted nanosponges were labeled 
with near-infrared fluorophores and Nanogold® to allow for in vivo optical imaging of 
nanoparticle biodistribution and ultrastructural studies with transmission electron 
microscopy (TEM) showing tumor targeting at the cellular level. In vitro studies compare 
drug loaded nanoparticles (NP PTX and NP CPT) in sequential, simultaneous and single 
drug treatment to determine the optimum combination and sequence (see chapter 3). 
Based on these findings, tumor targeted nanoparticles loaded with paclitaxel and 
camptothecin (HVGGSSV-NP PTX and HVGGSSV-NP CPT) are then administered 
sequentially in an in vivo lung cancer mouse model to study therapeutic efficacy of 
sequential treatment compared to controls. The following new findings are presented: (1) 
sequential administration of paclitaxel prior to camptothecin increases G2 cell cycle 
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arrest compared to simultaneous treatment in lung cancer cells (see chapter 3) (2) 
nanosponge formulation affords metronomic delivery of these drugs in vitro and in vivo 
(3) Tumor-specific targeting lowers increases bioavailability and enhances metronomic 
therapy.  
 
Experimental Materials and Methods 
Nanoparticle Preparation 
Materials 
Chemical reagents were purchased from Sigma-Aldrich and Strem Chemicals, 
chemotherapeutic drugs from LC Laboratories. Peptides (GCGGGNHVGGSSV) were 
purchased from EZBiolab Inc. (Carmel, IN). Spectra/Por Dialysis membrane 
(MWCO=10,000) in 0.05% sodium azide was purchased from Spectrum Laboratories.  
Characterization 
NMR Spectroscopy.  All 1H NMR spectra were acquired using a 400 MHz Bruker AV-
400 NMR with deuterated chloroform (CDCl3) and tetramethylsilane as internal standard. 
Peptide labeled nanoparticles were analyzed using a 600 MHz Bruker AV-II NMR with 
deuterated dimethyl sulfoxide (DMSO-d6) and tetramethylsilane as internal standard. 
Purification. Biotage Isolera Spektra One flash purification system equipped with a UV λ 
absorbance detector was used to purify AVL monomers. Purification was performed 
using a SNAP HP 50 g silica column with a 5-20% ethyl acetate gradient in n-hexanes 
with a flow rate of 50 ml/min. All monomers (AVL and VL) were vacuum distilled using 
a Kugelrohr distillation apparatus (Sigma Aldrich). 
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Gel-permeation chromatography (GPC). All GPC was performed using a Waters 
chromatography system equipped with refractive index and dual λ absorbance detectors, 
four 5 mm Waters columns (300 mm x 7.7 mm) with pore size (100, 1000, 100,000 and 
1,000,000 Å respectively). All samples were dissolved in tetrahydrofuran (THF), with a 
20 µl injection volume and 1 mL/min flow rate. 
Transmission electron microscopy (TEM). TEM imaging was performed on nanoparticles 
by dissolving approximately 5 mg in a solution of 1:0.4 mL isopropanol/acetonitrile. The 
dissolved nanoparticles were sonicated for 5 minutes and stained with 4 drops of a 3% 
phosphotungstic acid/water solution for 10 minutes. This solution was sonicated once 
more for 5 minutes before the copper grids were prepared. Ultrathin Carbon Type-A 400 
mesh copper grids (Ted Pella, Redding, CA) were gently immersed into the stained 
nanoparticle solution and allowed to dry for 2 hrs prior to analysis. A 200 kV Philips 
CM20T transmission electron microscope was used to acquire micrographs of the 
nanoparticles. 
Preparation of Monomers 
δ-valerolactone monomer (VL) 
Technical grade δ-valerolactone was Kugelrohr distilled to produce a colorless liquid 
product.  
α-allyl-δ-valerolactone monomer (AVL) 
A flame dried 500 mL two-necked round bottom flask was equipped with a stir bar, 
sealed with a rubber septum, and purged with nitrogen for 30 min. To the flask, 156.25 
mL of anhydrous THF was added and cooled to -78 °C in a dry ice/acetone bath. 
Following this, a basic solution of lithium diisopropylamine was produced by adding 
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redistilled n,n-diisopropylamine (3.3 mL, 23.63 mmol) and n-butyl lithium (2.5 M in 
hexanes) (9.35 mL, 23.38 mmol) dropwise via syringe. This solution was stirred for 20 
minutes. A nitrogen purged solution of distilled δ-valerolactone (1.97 mL, 21.23 mmol) 
in anhydrous THF (56 mL) was then added dropwise via syringe over 30 min. After an 
additional 30 min of stirring, a nitrogen purged solution of allyl bromide (2.21 mL, 25.54 
mmol) in hexamethylphosphoramide (4.43 mL, 25.46 mmol) was added via syringe. The 
reaction mixture was warmed up to -40 ºC and stirred for 2 hrs. The reaction was 
quenched with excess NH4Cl solution. The crude product was concentrated via rotary 
evaporator, washed three times with saturated NaCl solution, and dried with anhydrous 
magnesium sulfate. The crude product was purified via column chromatography (Biotage 
Isolera), analyzed by thin layer chromatography and Kugelrohr distilled. 
Chromatography with a gradient of 5-20% ethyl acetate in n-hexanes as eluent gave a 
yellow liquid product. Kugelrohr distillation produced a colorless liquid product. Yield: 
3.56 g (89%). 1H NMR (400MHz, CDCl3/TMS, ppm) δ: 5.7 (m, 1H, H2C=CH-), 5.08 (m, 
2H, H2C=CH-), 4.28 (m, 2H, -C(O)OCH2-), 2.53-2.58 (m, 2H, H2C=CHCH2-), 2.27 (m, 
1H, H2C=CHCH2CH-), 2.06 (m, 1H, H2C=CHCH2CHCH2-), 1.89 (m, 2H, 
C(O)OCH2CH2-), 1.55 (m, 1H, H2C=CHCH2CHCH2-). 
 
Preparation of Linear Polymer Precursors 
Poly(VL-co-AVL) from Sn(OTf)2 catalyst 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed 
with rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in 
anhydrous tetrahydrofuran was prepared (1.7 M) in a 50 mL flame dried and nitrogen 
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purged round bottom flask, and a stock solution of Sn(OTf)2 catalyst in anhydrous 
tetrahydrofuran was prepared (3.7x10-2 M) in a 10 mL flame dried and nitrogen purged 
round bottom flask.  Ethanol (584 µL, 1.0 mmol) and Sn(OTf)2 (261 µL, 9.64 x 10-6 mol) 
were added via syringe to the 25 mL 3-neck round bottom flask and the catalyst/initiator 
solution was allowed to stir at room temperature for 30 minutes prior to simultaneous 
addition of δ-valerolactone (2.22 g, 22.0 mmol) and α-allyl(valerolactone) (0.777 g, 
5.548 mmol) monomers via syringe.  After addition of both monomers, the reaction was 
stirred for 24 hrs at room temperature. The resulting polymer was diluted with 1 mL 
anhydrous THF and purified by dropwise addition into 1 L of chilled methanol to remove 
any remaining monomer and catalyst. The methanol was decanted and the precipitate 
dissolved in methylene chloride, rotary evaporated and dried in vacuo. The resulting 
polymer was observed as a waxy white solid.  Mw = 3000 Da; PDI = 1.09; 1H NMR (400 
MHz, CDCl3/TMS, ppm) δ: 5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 (m, -CH2-O-), 
3.64 (m, CH3CH2O-), 2.34 (m, vl, -CH2CH2C(O)O-, avl, H2C=CHCH2CH-, 
H2C=CHCH2CH-), 1.68 (m, avl and vl, -CHCH2CH2-), 1.26 (t, CH3CH2O-). 
Poly(VL-co-AVL) from Sn(Oct)2 catalyst 
A flame dried 25 mL 3-necked round bottom flask was equipped with a stir bar, sealed 
with rubber septa and nitrogen purged. A stock solution of anhydrous ethanol in 
anhydrous tetrahydrofuran was prepared (1.7 M) in a 25 mL flame dried and nitrogen 
purged round bottom flask, and a stock solution of Sn(Oct)2 catalyst in anhydrous 
tetrahydrofuran was prepared in a 10 mL flame dried and nitrogen purged round bottom 
flask. Ethanol (360 µL, 6.14 x10-1 mol) and Sn(Oct)2 (330 µL, 1.22 x 10-2 mol) were 
added via syringe to the 50 mL 3-neck round bottom flask and the catalyst/initiator 
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solution was allowed to stir at room temperature for 30 minutes prior to simultaneous 
addition of δ-valerolactone (2.46 g, 28.53 x 10-3  mol) and α-allyl(valerolactone) (0.93 g, 
7.134 x 10-3 mol) monomers via syringe.  After addition of both monomers, the reaction 
was stirred for 48 hrs at 105 °C in an oil bath. The resulting polymer was diluted with 1 
mL methylene chloride and purified by dropwise addition into 1.5 L of chilled diethyl 
ether to remove any remaining monomer and catalyst. The ether was decanted and the 
precipitate dissolved in methylene chloride, rotary evaporated and dried in vacuo. The 
resulting polymer was observed as a viscous yellow liquid.  1H NMR (300 MHz, 
CDCl3/TMS, ppm) δ: 5.72 (m, H2C=CH-), 5.04 (m, H2C=CH-), 4.08 (m, -CH2-O-), 3.64 
(m, CH3CH2O-), 2.34 (m, vl, -CH2CH2C(O)O-, avl, H2C=CHCH2CH-, H2C=CHCH2CH-
), 1.68 (m, avl and vl, -CHCH2CH2-), 1.26 (t, CH3CH2O-). 
Poly(VL-co-AVL-co-EVL) 
In a 100 mL round bottom flask, equipped with stir bar and rubber septum, a solution of 
poly(VL-co-AVL) (1.0 g, 1.55 x 10-3 mol) was dissolved in 8.5 mL of methylene 
chloride. To this solution, meta-chloroperoxybenzoic acid (121.25 mg, 7.03 x 10-4 mol) 
was added. The solution was stirred for 24 hrs at room temperature and then concentrated 
via rotary evaporator. The crude product was dissolved in a minimal amount of 
dichloromethane (2 mL) and precipitated into an Erlenmeyer flask containing 500 mL 
cold diethyl ether. The solution was decanted, and the white solid was rotary evaporated 
and dried in vacuo to obtain the final white waxy polymer. Yield: 0.768 g (76.8%). 1H 
NMR (400MHz, CDCl3/TMS, ppm) δ: Decrease in allylic protons at 5.7 and 5.09 ppm 
and the appearance of small broad resonance peaks at 2.96, 2.75 and 2.47 ppm due to the 
formation of the epoxide.  
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Formation of nanosponges 
In a 250 mL round bottom flask equipped with stir bar and reflux condenser, a solution of 
2,2'-(ethylenedioxy) diethylamine (10.5 µL, 7.18x10-5 mol) in 29.55 mL methylene 
chloride was heated at 45 °C. A solution of poly(VL-co-AVL-co-EVL), (0.200 g, Mw = 
3000 Da) dissolved in methylene chloride was added. The mixture was refluxed at 45 ºC 
for 12 hrs. Residual diamine crosslinker was removed via dialysis against methylene 
chloride with Spectra/Por Dialysis Tubing (MWCO = 10,000). Nanosponges were made 
from poly(VL-co-AVL) using Sn(OTf)2 and Sn(Oct)2 catalysts. 1H NMR (400 MHz, 
CDCl3/TMS, ppm) δ: Decrease in number of epoxide protons at 2.96, 2.75 and 2.47 ppm 
and the appearance of signals at 3.5 and 2.89 ppm corresponding to the protons near the 
secondary amine of the diamine crosslinker after the reaction. 
Addition of targeting peptide via photoinitiated thiol-ene ‘click’ reaction 
Poly(VL-co-AVL-co-EVL) nanoparticles were dissolved in dichloromethane and purified 
using Sephedex column chromatography, rotary evaporated and dried in vacuo. 
Anhydrous, degassed DMSO (1 mL) was used to dissolve 20 mg of poly(VL-co-AVL-
co-EVL) nanoparticles, 7.2 mg of GCGGGNHVGGSSV peptide (EZ BioLabs) and 3.4 
mg DMPA (2 eq. with respect to peptide). Mixture was stirred for 2 days in an oil bath at 
37 °C under ultraviolet light at 365 nm. The product was purified by dialysis (MWCO = 
10,000) against methanol/acetonitrile (1:1) for 2 days, rotary evaporated and dried in 
vacuo.  
Quantification of peptide units on nanoparticles via 1H NMR: 
Since the primary thiol functional group from the cysteine residue in the peptide 
(GCGGGNHVGGSSV) reacts with the allyl groups in the nanoparticle in a 1:1 
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stoichiometry, the allyl groups that are consumed in the reaction directly correlate with 
how many peptides are bound to the nanoparticle. By comparing the percent allyl groups 
in the nanoparticle before and after peptide attachment, the difference can be used to 
calculate the number of bound peptides. The nanoparticle peak at 4.08 ppm is used as an 
internal standard for determining the number of unmodified allyl groups remaining after 
the photoinitiated thiol-ene click reaction for peptide attachment. 
Modification of HVGGSSV-NPs for in vivo NIR imaging with NHS Alexa Fluor 750 and 
Mono-Sulfo-NHS Nanogold® 
HVGGSSV modified poly(VL-co-AVL-co-EVL) nanoparticles (30 mg) and unmodified 
nanoparticles (30 mg) were separately dissolved in anhydrous DMSO (600 uL). To each 
solution, NHS Alexa Fluor 750 (75 uL) and Mono-Sulfo-NHS Nanogold® (10 uL) was 
added simultaneously and the resulting mixture was stirred for 6 hrs (covered in foil to 
protect from light). The product was purified by dialysis (MWCO=10,000) against 
methanol/acetonitrile (1:1) overnight, rotary evaporated and dried in vacuo (covered in 
foil to protect from light).  
Cell Culture  
Murine Lewis lung carcinoma (LLC) cells were obtained from the American Type 
Culture Collection (Rockville, MD,). They were grown to 70% confluence in Dulbecco’s 
Modified Eagle Medium supplemented with 10% fetal bovine serum and 1% 
antibiotic/antimycotic. All cultures maintained at 37°C in incubator with 95% humidity 
and 5% CO2. 
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Animal models 
Male athymic nude mice (nu/nu) and C57BL6 mice were purchased from Harlan 
Laboratories (Indianapolis, IN). All in vivo animal protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC). Animals were anesthetized 
using a ketamine and xylazine solution prior to injection of 1 x 106 LLC cells 
subcutaneously in the hind limbs. Once tumors reached an approximate size of 0.5 cm in 
diameter mice were used for in vivo studies.  
Radiation treatment 
In order to stimulate expression of radiation-induced TIP-1 in tumors, each tumor was 
treated with sub-therapeutic levels of ionizing radiation prior to drug administration. 
Mice were anesthetized to inhibit movement and covered with lead blocks of 1 cm 
thickness, leaving only the hind limb tumor exposed for treatment. Tumors were treated 
with 3 Gy ionizing radiation at 300 kV, using a Pantak Therapax 3 linear accelerator 
system (Pantak), with an adjustable collimator set to focus dosage exclusively to tumors. 
Four hours following irradiation, mice were intravenously administered nanoparticle drug 
treatments via lateral tail vein.  
NIR fluorescence imaging and analysis 
Near-infrared (NIR) fluorescence imaging was done on athymic nude mice using a 
Xenogen IVIS 200 small animal imaging system (Xenogen Inc., CA). A filter with 
excitation and emission at 680/775 nm was used for acquisition of all images. Briefly, a 
single dose of 3 Gy radiation was given to tumors in mice receiving targeted HVGGSSV-
NP and no radiation was applied for HVGGSSV-NP controls and untargeted controls. 
Four hours after irradiation, nanoparticles were injected. At 24 hrs post-injection, mice 
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were immobilized with continuous administration of isoflurane gas, and images were 
acquired, with exposure times of 1 second and an f/stop of 2.  In order to compare 
fluorescence in tumor regions quantitatively, regions of interest (ROIs) were created over 
tumor areas, and the total radiance for each ROI was measured in p/s/cm2/sr. Results are 
presented as mean and standard error for groups of three mice. 
Tumor growth delay studies  
For in vivo studies, six-week-old male C57BL6 mice were used. All mice were injected 
with 1 x 106 LLC cells subcutaneously above their right hind limbs. Tumor volume was 
measured manually using calipers, and tumor volume was calculated using the formula: 
volume = 0.5 (length x width2). Upon reaching an approximate diameter of 0.5 cm, mice 
were divided into groups and administered nanoparticle drug conjugates (10 mg/kg 
calculated for amount of each drug, 50-100 µL volume in PBS) intravenously through 
lateral tail vein. Mice receiving targeted treatments on day 1, were given 3 Gy radiation 
and injected 4 hrs later with either HVGGSSV-NP PTX, HVGGSSV-NP CPT, or 
HVGGSSV-NP PTX (day 1) à HVGGSSV-NP CPT (day 9). Mice receiving untargeted 
treatments on day 1 were given no radiation and injected with NP PTX, NP CPT, or 
systemic (free) PTX. Mice receiving radiation (RT) only on day 1 received 3 Gy 
radiation, and mice receiving no drug (control) on day 1 were injected with PBS vehicle. 
Tissue transmission electron microscopy (TEM) 
Peptide modified nanoparticles labeled with Nanogold® were injected intravenously via 
lateral tail vein in a volume of 0.1-0.2 mL. At 24 hrs after injection, tumor tissues were 
excised and cut into 1-2 mm3 cubes with a razor blade and fixed in a solution of 3% 
glutaraldehyde in cacodylate buffer overnight at 4 °C. Tissue sections were subsequently 
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fixed in 2% osmium tetroxide in 100 mM cacodylate buffer, pH 7.4, overnight at 4 °C. 
Following treatment with 2% uranyl acetate for 48 hrs at 37 °C, tumor tissues were 
embedded in epoxy resin and thick-sectioned. Regions of interest were selected under a 
light microscope and recut into thin sections subsequently stained with lead citrate. 
Sections were placed onto copper grids and examined with a Philips/FEI T-12 high-
resolution transmission electron microscope with a 2000 x 2000 AMT CCD camera 
system. Acquired images were then analyzed using AMT image capture software. 
Drug quantification 
At determined time points (days 2, 7, 14, 23) following injections, tumors were excised 
and homogenized. Tumor tissue homogenates (200 µL) were extracted by protein 
precipitation with 500 µL acetonitrile spiked with 100 µL internal standard. Samples 
were vortexed and centrifuged for 10 minutes at 3000 rpm. The supernatant was then 
filtered using centrifugal filters (Amicon Ultra, Millipore) for another 30 minutes at 3000 
rpm, and the resulting filtrate was evaporated. It was reconstituted in 20 mM ammonium 
formate in acetonitrile/water (1:1) and analyzed by HPLC/MS using a Phenomenex Luna 
C18 analytical column, with an injection volume of 20 µL and flow rate of 300 
µL/minute. Mobile phase A was 20 mM ammonium formate in water/acetonitrile (95:5, 
v:v) and mobile phase B was 20 mM ammonium formate in water/acetonitrile (5:95, v:v). 
Immunohistochemistry 
To determine changes in cell proliferation, cell death and tumor vascular density in vivo, 
six-week-old male C57BL6 mice were injected with 1 x 106 LLC cells subcutaneously 
above their right hind limbs. Upon reaching an approximate diameter of 0.5 cm, mice 
were divided into groups and administered drug loaded nanoparticles (10 mg/kg 
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calculated for each drug, 50-100 µL volume in PBS) intravenously through lateral tail 
vein. Mice receiving targeted treatments on day 1, were given 3 Gy radiation and injected 
4 hrs later with either HVGGSSV-NP PTX, HVGGSSV-NP CPT, or HVGGSSV-NP 
PTX (day 1) à HVGGSSV-NP CPT (day 9). Mice receiving untargeted treatments on 
day 1 were given no radiation and injected with either NP PTX or NP CPT. Mice 
receiving no drug (control) on day 1 were injected with PBS vehicle. Fourteen days 
following injections, tumors were excised and fixed in a solution of 10% formalin for 48 
hrs. Paraffin-embedded tissues were sectioned into 10 µm thick sections and treated with 
anti-cleaved caspase-3 antibody for detection of apoptotic cells, anti-Ki67 antibody for 
detection of cell proliferation, and anti-CD31 antibody for detection of blood vessels. 
Slides were viewed using a Zeiss Axiophot wide field microscope, and images taken at 
10x magnification. Images were acquired from three fields of view and the number of 
cells expressing either cleaved caspase-3, Ki67, or CD31 was counted. Dark stained 
nuclei were scored positive, and blue nuclei were scored as negative. Bar graphs shown 
represent the number of cells as a percentage of total cells counted. All images were 
analyzed using MetaMorph image acquisition and analysis software. 
Statistical analysis 
Statistical analysis was performed using mean and standard error (SE), with student’s t 
test and p values less than 0.05 considered significant. P values are shown on bar graphs 
with asterisks, where * represents p ≤ 0.05, ** represents p ≤ 0.01, and *** represents p ≤ 
0.001 per statistical convention.  
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Results and discussion 
Previously, the HVGGSSV peptide has been shown to have tumor-specific binding to the 
TIP-1 protein found in irradiated tumors.14, 28 In this study we report the use of 
HVGGSSV peptide for targeting of polyester nanoparticles in a murine LLC tumor 
model. Nanoparticles were synthesized and functionalized with HVGGSSV peptide 
(HVGGSSV-NP), and labeled with Alexa Fluor® 750 near-infrared fluorophore (Figure 
5.1A,B). These targeted fluorescent nanoparticles were then injected into nude mice with 
irradiated LLC tumors, and imaged via NIR fluorescent imaging to visualize tumor 
binding in vivo (Figure 5.2A). At 24 hrs post-injection, mice receiving HVGGSSV 
targeted nanoparticles exhibited 7.9 times greater fluorescence in irradiated tumors 
compared to unirradiated controls, and over two times greater fluorescence compared to 
untargeted nanoparticle controls (Figure 5.2B). In order to determine specifically where 
in the tumor tissue these targeted nanoparticles were delivered, targeted and untargeted 
nanoparticles were functionalized with Nanogold® (Figure 5.1C). 
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Figure 5.1. Synthesis of polyester nanoparticles functionalized with HVGGSSV 
targeting peptide (A) and Alexa Fluor® 750 near-infrared fluorophore imaging agents (B) 
and Nanogold® -HVGGSSV nanoparticles (C). 
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Figure 5.2. Near-infrared (NIR) fluorescence imaging of HVGGSSV-NPs in an LLC 
model at 24 hrs post-injection (A). Nude athymic mice with heterotopic tumors (right 
hind limb) were intravenously injected with untargeted nanoparticle controls and 
unirradiated (0 Gy) (left), HVGGSSV-NPs in unirradiated (0 Gy) tumor controls 
(middle), or HVGGSSV-NPs in irradiated (3 Gy) tumors (right). Radiance for 
HVGGSSV-NPs in irradiated tumors and unirradiated control tumors compared to 
untargeted nanoparticle controls (B). Color scale bar, radiance in units of 
photons/s/cm2/sr. Bars, mean and SE for n=3, unpaired Student’s t test (p<0.05). 
 
These small (1-2 nm) gold particles have high electron density, producing enhanced 
image contrast in TEM due to greater absorption of these electrons at lower 
magnification. Nanogold® functionalized HVGGSSV-NP and untargeted NP controls 
were injected intravenously into C57BL6 mice and tumors excised 24 hrs post-injection. 
TEM images show preferential accumulation of Nanogold (seen as black ‘dots’ in yellow 
regions of interest) within tumor vascular endothelium in HVGGSSV targeted tumors but 
not in untargeted control tumors at 24 hrs (Figure 5.3 A,B). Areas with higher 
concentrations of Nanogold indirectly show presence of HVGGSSV targeted 
nanoparticles (see insets), and confirm tumor-specific binding of these nanoparticles 
compared to untargeted controls.  
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Figure 5.3. TEM micrographs of LLC tumors treated with Nanogold® labeled 
HVGGSSV-NPs in a murine model at 24 hrs post-injection. C57BL6 mice with 
heterotopic tumors (right hind limb) were intravenously injected with (A) Nanogold® 
labeled HVGGSSV-NP in irradiated (3 Gy) tumors or (B) untargeted nanoparticle 
controls. Tumors were excised at 24 hrs post injection, fixed and processed for TEM 
analysis. A cross-section of a tumor blood vessel is shown in each micrograph. 
Nanoparticles (dark spheres indicated by arrows and yellow regions of interest) can be 
seen localized inside tumor microvascular endothelial cells. Scale bar indicates 2 µm. 
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Based on the results observed in vitro (see chapter 3), the nanoparticle drug combination 
and sequence with the greatest therapeutic effect on cells was selected for 
functionalization with tumor-specific peptide HVGGSSV, and was tested in vivo to 
evaluate tumor-specific targeting, drug delivery and therapeutic efficacy. Specifically, 
sequential targeted HVGGSSV-NP PTX à HVGGSSV-NP CPT (i.e. HVGGSSV-NP 
paclitaxel administered before HVGGSSV-NP camptothecin) was compared to targeted 
and untargeted monotherapy controls, radiation only, and untreated controls. To evaluate 
therapeutic efficacy, tumor growth delay studies in a LLC model were performed to 
compare the tumor volume doubling time across different treatment groups. Figure 5.4A 
shows that untargeted monotherapy controls showed no significant tumor growth delay 
compared to untreated controls, with radiation only and systemic (free) paclitaxel 
controls showing a slight increase (1 day). Both HVGGSSV targeted NP PTX and NP 
CPT showed significant growth delay compared to untargeted controls (4 days). 
Sequential injection of camptothecin 8 days after paclitaxel administration produced a 
tumor doubling time of 21 days vs. 9 days for HVGGSSV targeted single drug controls 
(Figure 5.4B). The greatest growth delay was observed between sequential targeted 
treatment groups and untargeted single drug controls (16 days) (Figure 5.4A).  
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Figure 5.4.  Tumor growth delay analysis of HVGGSSV peptide targeted nanoparticles 
loaded with paclitaxel or camptothecin. C57BL6 mice with LLC tumors grown on hind 
limbs were irradiated with 3 Gy on day 1 and injected 4 hrs later with either HVGGSSV-
NP PTX, HVGGSSV-NP CPT, HVGGSSV-NP PTX à HVGGSSV-NP CPT, NP PTX, 
NP CPT, systemic (free) PTX, radiation only, or untreated. Sequential HVGGSSV-NP 
PTX à HVGGSSV-NP CPT treatment group was given second injection on day nine. 
All drugs were administered at a dose of 10 mg/kg, intravenously via tail vein (A).Time 
in days for tumors to reach two-fold volume (B). Bars, mean and SE for n=3, unpaired 
Student’s t test (p<0.05). 
 
To validate presence of drugs in tumor tissues, analytical HPLC/MS was used to quantify 
drug levels at 2, 7, 14 and 23 days post-injection. Tumors treated with targeted 
HVGGSSV-NP PTX showed the highest levels of paclitaxel at day 2 post-injection with 
continued presence of paclitaxel up to 23 days post-injection as shown in Figure 5.5A. 
Tumors treated with targeted HVGGSSV-NP CPT showed similar levels of camptothecin 
over time, in lower concentrations at day 2, with steady concentrations up to day 23 as 
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well. Chromatograms of both drugs present in sequentially treated HVGGSSV-NP PTX 
à HVGGSSV-NP CPT tumor tissues can be seen at day 14 (Figure 5.5B). Differences in 
metabolism, elimination and half-life for each drug can cause changes in drug levels seen 
over time, with NP CPT showing faster metabolism and elimination compared to 
paclitaxel. Continuous and steady levels of both drugs can be seen from day 7 to 23, 
indicating sustained and linear levels of drug release from nanoparticles over time, which 
is important for metronomic chemotherapy (Figure 5.5A). 
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Figure 5.5. Quantification of paclitaxel and camptothecin content in LLC tumor tissues 
following treatment with HVGGSSV-NP PTX, HVGGSSV-NP CPT, and HVGGSSV-
NP PTX à HVGGSSV-NP CPT. Concentrations of paclitaxel and camptothecin in 
tumors at 2, 7, 14 and 23 days post-injection (A). PTX and CPT levels in untargeted 
controls were below the limit of detection (indicated by #). Chromatograms for tumor 
tissue excised at 14 days post-injection show presence of paclitaxel (top) and 
camptothecin (bottom) (B). 
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To determine the mechanism of cell death, further immunohistochemical analyses were 
performed on tumor tissues to probe for cell proliferation, cell death and microvascular 
endothelial cells. Cellular proliferation seen with sequentially targeted treatment (i.e. 
HVGGSSV-NP paclitaxel administered before HVGGSSV-NP camptothecin) was 
significantly decreased compared to targeted camptothecin monotherapy and untreated 
controls, but not targeted paclitaxel monotherapy controls (Figure 5.6A,B).  
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Figure 5.6. Immunohistochemical analysis of cell proliferation. C57BL6 mice with LLC 
tumors were treated with saline (control), NP PTX, HVGGSSV-NP PTX, NP CPT, 
HVGGSSV-NP CPT, or sequential HVGGSSV-NP PTX à HVGGSSV-NP CPT for 
fourteen days. Paraffin sections were stained for cell proliferation via Ki67 nuclear 
protein (A). All sections were counterstained with hematoxylin. Dark stained nuclei were 
scored as positive, and blue nuclei were scored as negative. Zeiss Axiophot, 10x 
magnification, scale bar indicates 100 µm. Percentage of proliferating cells in all 
treatment groups (B). Bars show mean and SE for n=3, unpaired Student’s t test (p<0.05). 
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Sequentially targeted treatment achieved the greatest number of caspase-3 positive 
apoptotic cells, with over 5 times higher levels of apoptosis compared to both 
monotherapy and untreated controls (Figure 5.7A,B).  
 
Control HVG-NP PTX 
HVG-NP CPT 
HVG-NP PTX ! 
HVG-NP CPT 
NP PTX 
NP CPT 
A B 
0.0 
5.0 
10.0 
15.0 
20.0 
Co
ntr
ol 
NP
 P
TX
 
HV
G-
NP
 P
TX
 
NP
 C
PT
 
HV
G-
NP
 C
PT
 
HV
G-
NP
 P
TX
 --
> H
VG
-N
P C
PT
 
%
 A
po
pt
ot
ic
 C
el
ls
 
(C
as
pa
se
-3
) 
** ** 
 
 
Figure 5.7. Immunohistochemical analysis of cell death. C57BL6 mice with LLC tumors 
were treated with saline (control), NP PTX, HVGGSSV-NP PTX, NP CPT, HVGGSSV-
NP CPT, or sequential HVGGSSV-NP PTX à HVGGSSV-NP CPT for fourteen days. 
Paraffin sections were stained for apoptosis by presence of active caspase-3 (A).  All 
sections were counterstained with hematoxylin. Dark stained nuclei were scored as 
positive, and blue nuclei were scored as negative. Zeiss Axiophot, 10x magnification, 
scale bar indicates 100 µm. Percentage of apoptotic cells in all treatment groups (B). Bars 
show mean and SE for n=3, unpaired Student’s t test (p<0.05). 
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Additionally, sequentially targeted groups displayed fewer blood vessels overall 
compared to targeted paclitaxel and camptothecin monotherapy and untreated controls 
(Figure 5.8A,B).  
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Figure 5.8. Immunohistochemical analysis of tumor vascularity. C57BL6 mice with LLC 
tumors were treated with saline (control), NP PTX, HVGGSSV-NP PTX, NP CPT, 
HVGGSSV-NP CPT, or sequential HVGGSSV-NP PTX à HVGGSSV-NP CPT for 
fourteen days. Paraffin sections were stained for CD31 expression on vascular 
endothelium (A).  All sections were counterstained with hematoxylin. Dark stained nuclei 
were scored as positive, and blue nuclei were scored as negative. Zeiss Axiophot, 10x 
magnification, scale bar indicates 100 µm. Percentage of vascular density in all treatment 
groups (B). Bars show mean and SE for n=3, unpaired Student’s t test (p<0.05). 
 
These results suggest that paclitaxel is more influential in inhibiting cell 
proliferation and camptothecin is driving the anti-angiogenic effect by reducing the 
number of blood vessels, thus inhibiting access to nutrients and growth factors necessary 
for continued tumor growth. Therefore, targeted sequential treatment with these two 
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drugs produces a more powerful effect than either drug alone. This optimized effect may 
be due to paclitaxel enhancing sensitivity to camptothecin, resulting in cells undergoing 
G2/M phase arrest and inducing apoptotic cell death. Subsequent administration of 
camptothecin results in a decrease in vascular density and reduction in blood flow 
available to tumors, further enhancing apoptotic effects produced by exposure to 
paclitaxel. In addition to these effects, decreased cell proliferation observed in the 
sequential sequence validate results from in vitro studies (see chapter 3) where treatment 
with paclitaxel followed by camptothecin produced the greatest changes in microtubule 
morphology and decreased the number of proliferating cells. These results jointly suggest 
enhanced sensitivity of cells to camptothecin after treatment with paclitaxel and indicate 
this drug sequence as having the greatest biological effect in vitro and in vivo. 
Prior studies using the nanosponge delivery system have demonstrated the 
importance of targeting and the unique features of the nanosponge for supporting drug 
solubilization and release, resulting in greater drug efficacy. 10 This study investigated the 
feasibility of tumor-specific delivery and metronomic release of paclitaxel and 
camptothecin to determine the optimum drug combination and sequence for treating lung 
cancer. Initial studies (see chapter 3), examined the role of drug combination and 
sequence in vitro, in both mouse and human lung cancer cell lines, with synthesized 
untargeted nanosponges loaded with either paclitaxel (NP PTX) or camptothecin (NP 
CPT). Results showed not only that paclitaxel and camptothecin combination therapy 
produced the greatest G2/M phase arrest compared to monotherapy, but also that 
sequential administration of NP PTX followed by NP CPT further enhanced caspase-
dependent cell death compared to simultaneous administration. Paclitaxel, more so than 
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campthothecin, was observed to drive cells into G2/M phase arrest and subsequent 
apoptosis. Further studies are necessary to determine the molecular basis for this effect in 
lung cancer. Sequential administration (NP PTX → NP CPT) of nanoparticle drug 
delivery systems resulted in greater cell death and decreased cell proliferation.  
These results were validated in an in vivo mouse model of lung cancer after tumor 
binding of HVGGSSV functionalized targeted nanoparticles (Figure 5.1A-B) were 
confirmed. The targeting enabled nanoparticles to be selectively and specifically guided 
to tumors within 24 hrs after injection (Figure 5.2). TEM images showed preferential 
intracellular accumulation of Nanogold® functionalized targeted nanoparticles (Figure 
5.1C) in tumor vascular endothelial cells at 24 hrs compared to untargeted controls 
(Figure 5.3). Use of the targeted nanoparticle drug delivery system in a sequential 
paclitaxel à camptothecin scheme demonstrated greater cell death, decreased cell 
proliferation and vascular density (Figure 5.7, 5.6, 5.8), translating to increased 
therapeutic efficacy in an in vivo lung cancer model. In vitro studies (see chapter 3) 
showed that the greatest changes in microtubule morphology were seen in cells exposed 
to paclitaxel à camptothecin sequential treatment, and this specific order suggests an 
increased sensitivity to camptothecin following paclitaxel exposure. Based on these 
results, the best drug combination and sequence was selected for targeting and 
therapeutic studies in vivo. Therapeutic efficacy studies conducted with sequential 
HVGGSSV targeted NP PTX and NP CPT showed 2.3 fold greater tumor growth delay 
in combination versus monotherapy treated groups, and 4.2 fold greater delay compared 
to untargeted and systemic (free) drug controls (Figure 5.4). Additionally, effects of these 
two drugs in combination on tumor angiogenesis were studied to determine changes in 
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vascular density (Figure 5.8A,B). Tumor neovasculature presents an attractive therapeutic 
target, with its role in providing nutrients and growth factors to growing tumors, as well 
as abnormally permeable architecture.29 Disrupting blood flow to tumors provides a key 
element in many therapies as it diminishes tumor access to vital growth factors needed 
for continued growth, invasion and metastasis. Drugs with anti-angiogenic properties, 
like camptothecin, provide not only cytotoxic effects to tumor cells, but also damage their 
associated vasculature, providing multiple benefits as demonstrated. Moreover, use of 
nanoparticle carriers with controlled and sustained low dose drug release allows for 
metronomic chemotherapy, which has been shown to enhance anti-angiogenic effects.30  
 
Conclusion 
In conclusion, sequential paclitaxel à camptothecin chemotherapy exhibited a 
‘priming’ effect on lung cancer cells that enhanced camptothecin’s effect on cells when 
given second. Nanosponge functionalization with targeting and imaging agents, sustained 
drug release profiles, and improved water solubility make them ideal for metronomic 
chemotherapy. Tumor-specific targeting of nanosponges to radiation-induced receptors 
increased bioavailability and enhanced therapeutic efficacy. Additionally, radiation 
treatment is commonly included with many chemotherapy regimens, and presents a 
clinically relevant opportunity for combining nanomedicine treatments with 
radiosensitizing drugs like paclitaxel and camptothecin. 
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CHAPTER 6 
 
CONCLUSION AND FUTURE OUTLOOK 
 
Conclusions 
This work shows the development, optimization and evaluation of tumor-specific 
nanosponge drug delivery systems as chemotherapeutics. Nanoparticles made from 
biomedical polymers are commonly used in drug delivery applications because they 
allow for controlled release of drugs and degradation of nanoparticles over time. 
Development of nanoparticles for drug delivery and improved conjugating methods make 
it possible to design and create multifunctional nanoparticles for tumor-targeted drug 
delivery.  Multifunctional nanoparticles composed of biodegradable polymers can be 
used to deliver controlled release of therapeutic drugs, functionalized with imaging 
agents for diagnostic purposes, and tumor-specific ligands for targeting of cancer. In this 
work, biodegradable polymeric ‘nanosponges’ were used to optimize targeted delivery of 
paclitaxel and camptothecin to lung cancer. 
Linear polymers of narrow polydispersity were produced from tin (II) triflate 
catalyzed ring-opening polymerization methods in order to produce nanosponges with 
more uniform size distributions. These linear polymers showed greater monomer 
incorporation, higher yields, and faster reaction times at room temperature. By using 
‘nanosponges’ produced from these optimized linear polyester copolymers, greater 
control over size distribution was able to be achieved producing higher quality 
nanoparticles for in vitro and in vivo applications. These nanosponges were then loaded 
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with hydrophobic chemotherapy drugs paclitaxel and camptothecin for enhanced 
solubility and drug release properties.  
Initial studies were performed to determine the feasibility of using nanosponge 
encapsulated paclitaxel and camptothecin in combination treatment, and to determine the 
optimum drug combination and sequence for treating lung cancer. Here, the role of drug 
combination and sequence in vitro, in both mouse and human lung cancer cell lines, was 
investigated using synthesized nanosponges loaded with either paclitaxel (NP PTX) or 
camptothecin (NP CPT). Results showed not only that paclitaxel and camptothecin 
combination therapy produced the greatest G2/M phase arrest compared to monotherapy, 
but also that sequential administration of NP PTX followed by NP CPT further enhanced 
caspase-dependent cell death compared to simultaneous administration. Paclitaxel, more 
so than campthothecin, was observed to drive cells into G2/M phase arrest and 
subsequent apoptosis. The use of a sequential paclitaxel → camptothecin chemotherapy 
schedule was demonstrated to exhibit a “priming” effect on lung cancer cells that 
enhanced camptothecin’s effect on cells when given second.  
Nanosponges were functionalized with αvβ3 integrin targeting peptides such as 
cyclo RGD and a TIP-1 receptor targeting peptide HVGGSSV. These tumor targeting 
peptides allowed for greater tumor cell-specific delivery of drug-loaded nanosponges, 
optimizing bioavailability and therapeutic efficacy of chemotherapy drugs in tumors.  In 
addition, nanosponge functionalization with targeting and imaging agents, sustained drug 
release profiles, and improved water solubility make them ideal for combination 
treatment and metronomic chemotherapy. 
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While nanosponges are a suitable platform for the delivery of hydrophobic 
chemotherapy drugs, other types of nanoparticles have also been used in the literature to 
achieve this purpose. Micelles and liposomes, due to their lipophilic properties, have 
been used to encapsulate a variety of hydrophobic drugs for the treatment of cancer and 
other diseases. These nanoparticles, however, are often difficult to produce in uniform 
size distributions due to processing methods, and consistent production of nanoparticles 
in smaller size ranges (under 200 nm) remains difficult. As a result, these types of 
nanoparticles are not ideal for intravenous therapeutic applications, but can be used in 
other situations where nanoparticle size is not as critical an issue. In addition to micelles 
and liposomes, other types of nanoparticles such as dendrimer-based scaffolds have also 
been used to deliver hydrophobic drugs. These branched structures offer the opportunity 
for covalent attachment of many drug molecules directly to the scaffold, with different 
methods of cleavage and release of the drugs. Consequently, achieving more gradual drug 
release profiles tends to be more difficult as these methods of cleavage and release 
support more “burst-like” drug release profiles. Nanoparticles made from proteins, such 
as albumin, offer another way to deliver drug molecules to tissues, but also show more 
rapid initial drug release profiles. Comparing lipophilic micelles and liposomes, 
dendrimer-based and protein-based nanoparticles to nanosponges reveals advantages for 
delivery of chemotherapy drugs such as improved size dimensions and drug release 
profiles. These observations highlight the significance of application type to the selection 
of a suitable nanoparticle platform. Thus, matching the requirements of a particular 
application with the attributes of a nanoparticle is key for producing a drug delivery 
system that produces the desired effects.  
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The use of synergistic drug combinations, sequences and ratios presents an 
opportunity for customization of treatments to patients. Selection of drugs and drug 
combinations that an individual patient responds to best, tumor-specific targeting, and 
optimized dosing and delivery of drugs are all effective ways to personalize treatment 
and improve the likelihood of positive therapeutic outcomes while reducing adverse side 
effects. While many of the developments in personalized medicine require genomic 
information and are tailored to individual patients at the genetic level, the use of 
synergistic drugs in combination with nanoparticle drug delivery can help support 
customization of therapy alongside genetic analysis, and provide an excellent 
complement to modern personalized medicine.  
 
Future Aims 
Future studies using these nanosponges should explore a large panel of small 
molecule drugs of varying molecular weight, solubility, and hydrophobicity in order to 
determine the drugs that are best suited to this particular drug delivery system. In vitro 
studies examining the effect of varying nanoparticle drug release rates with drug 
combinations should be performed to determine if drug release rates can be tailored to 
produce optimal drug combination schedules. Synergistic drug combinations could be 
used in sequences that are administered as single bolus injections, with the drug release 
properties of the nanoparticle serving as modulators of sequence administration. Similar 
studies can also be done using nanoparticles of varying crosslinking density to produce 
drug combination cocktails that provide synergistic ratios of multiple drugs to tumors 
over time.  
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Additional areas for further work involve the development of OPD containing 
polymers. Reduction in polydispersity among OPD containing polymers is an area that 
needs to be explored in order to produce nanoparticles with more consistent uniform size 
distributions.  Further studies are also necessary to determine the ideal amount of OPD 
monomer incorporation in polyesters needed to produce polymers that are both water 
soluble while still retaining the ability to hold hydrophobic small molecule drugs. These 
polyesters also hold the potential for producing nanoparticles that can encapsulate 
hydrophilic drugs and small molecules, and this possibility is also worthy of further 
consideration. The studies contained in this work offer a potential starting point for 
investigating these opportunities in future works.  
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APPENDIX 
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Figure A. 1H NMR of δ-valerolactone monomer in CDCl3. 
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Drug Quantification 
 
A. 
 
 
 
B. 
 
Standard 
Specified 
Concentration 
(nM) 
Calculated 
Concentration 
(nM) 
% Diff 
P1 2000.0 1850.6 -7 
P2 1000.0 1159.2 16 
P3 200.0 196.7 -2 
P4 100.0 94.0 -6 
P5 20.0 19.1 -5 
P6 10.0 10.4 4 
 
Figure B.  Calibration curve for paclitaxel analyte using docetaxel as internal standard. 
Paclitaxel (internal standard, Docetaxel) was extracted from tumor tissue homogenate, 
producing a linear calibration curve over the dynamic range of 10-2000 nM with an r2 
coefficient of 0.9885. Samples were run in triplicate at concentrations of 10, 20, 100, 200, 
1000 and 2000 nM. (A) Paclitaxel standards show a linear fit over 10-2000 nM range. (B) 
Accuracy of paclitaxel standards extracted from tumor tissue. 
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B.  
 
Standard 
Specified 
Concentration 
(nM) 
Calculated 
Concentration 
(nM) 
% Diff 
C1 2000.0 2014.1 1 
C2 1000.0 1080.1 8 
C3 200.0 180.2 -10 
C4 100.0 97.1 -3 
C5 20.0 21.3 7 
C6 10.0 9.7 -3 
 
 
Figure C.  Calibration curve for camptothecin analyte using SN-38 as internal standard. 
Camptothecin (internal standard, SN-38) was extracted from tumor tissue homogenate, 
producing a linear calibration curve over the dynamic range of 10-2000 nM with a slope 
and intercept of y = 0.0002x - 0.001 and an r2 coefficient of 0.9985. Samples were run in 
triplicate at concentrations of 10, 20, 100, 200, 1000 and 2000 nM. (A) Camptothecin 
standards show a linear fit over 10-2000 nM range. (B) Accuracy of camptothecin 
standards extracted from tumor tissue. 
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Figure D. Calibration curve for camptothecin using UV-Vis spectrophotometry. 
Camptothecin was dissolved in DMSO at varying concentrations and absorbance was 
measured using UV-Vis NanoDrop. Samples were run in triplicate and a linear 
calibration curve was produced with a slope and intercept of y = 4.177x + 0 and an r2 
coefficient of 0.99841. 
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Figure E. Calibration curve for paclitaxel using UV-Vis spectrophotometry. Paclitaxel 
was dissolved in DMSO at varying concentrations and absorbance was measured using 
UV-Vis NanoDrop. Samples were run in quadruplicate and a linear calibration curve was 
produced with a slope and intercept of y = 0.3956x + 0.0029 and an r2 coefficient of 
0.98689.  
 
 
 
 
 
 
 
 
 
